BioRestorative Therapies (BRTX) S-1 3 Jun 15 IPO registration Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015
Document Information [Line Items]
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1505497
Entity Filer Category	Smaller Reporting Company
Document Type	S-1
Amendment Flag	FALSE
Document Period End Date	31-Mar-15

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash	$145,866	$91,798	$201,098
Inventories	1,927	1,945	17,965
Prepaid expenses and other current assets	32,438	20,570	20,739
Total Current Assets	180,231	114,313	239,802
Property and equipment, net	537,155	493,856	35,568
Intangible assets, net	1,094,913	1,037,732	1,107,545
Security deposit	45,900	45,900	0
Total Assets	1,858,199	1,691,801	1,382,915
Current Liabilities:
Accounts payable	1,265,550	1,111,879	1,269,970
Accrued expenses and other current liabilities	1,884,559	1,466,506	1,176,662
Accrued interest	97,816	94,026	65,909
Current portion of notes payable, net of debt discount of $60,332 and $113,257 at March 31, 2015 and December 31, 2014, respectively	5,463,291	5,688,239	4,990,009
Deferred revenues	210,882	164,349	0
Total Current Liabilities	8,922,098	8,524,999	7,502,550
Accrued interest, non-current portion	23,520	5,195	41,434
Notes payable, non-current portion	307,873	50,000	524,000
Total Liabilities	9,253,491	8,580,194	8,067,984
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares; none issued and outstanding at March 31, 2015 and December 31, 2014	0	0	0
Common stock, $0.001 par value; Authorized, 200,000,000 shares; Issued 37,750,173 and 34,511,800 shares at March 31, 2015 and December 31, 2014, respectively; Outstanding 37,191,552 and 33,953,179 shares at March 31, 2015 and December 31, 2014, respectively	37,750	34,512	19,633
Additional paid-in capital	19,759,105	18,509,121	13,139,712
Accumulated deficit	-27,160,147	-25,400,026	-19,812,414
Treasury stock, at cost, 558,621 shares at March 31, 2015 and December 31, 2014	-32,000	-32,000	-32,000
Total Stockholders' Deficiency	-7,395,292	-6,888,393	-6,685,069
Total Liabilities and Stockholders' Deficiency	$1,858,199	$1,691,801	$1,382,915

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current portion of notes payable, debt discount	$60,332	$113,257	$237,381
Non-current portion of notes payable, debt discount		$0	$3,110
Preferred stock, par value	$0.01	$0.01	$0.01
Preferred stock, Authorized	5,000,000	5,000,000	5,000,000
Preferred stock, issued	0	0	0
Preferred stock, outstanding	0	0	0
Common stock, par value	$0.00	$0.00	$0.00
Common stock, Authorized	200,000,000	200,000,000	200,000,000
Common stock, Issued	37,750,173	34,511,800	19,633,173
Common stock, Outstanding	37,191,552	33,953,179	19,074,552
Treasury stock, at cost, shares	558,621	558,621	558,621

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Revenues	$184,902	$375	$415,996	$1,680
Cost of sales	76,432	60	213,834	208
Gross Profit	108,470	315	202,162	1,472
Operating Expenses
Marketing and promotion	44,937	31,794	125,626	114,951
Consulting	365,069	267,198	1,310,121	779,462
Research and development	406,856	493,741	1,430,614	1,594,054
General and administrative	917,574	636,000	2,258,307	2,265,275
Total Operating Expenses	1,734,436	1,428,733	5,124,668	4,753,742
Loss From Operations	-1,625,966	-1,428,418	-4,922,506	-4,752,270
Other (Expense) Income
Interest expense	-64,640	-73,131	-285,275	-371,281
Amortization of debt discount	-69,515	-98,505	-464,470	-405,531
Loss on extinguishment of notes payable, net	0	-49,094	-49,094	-7,200
Warrant modification expense	0	-30,128	-50,035	-214,912
Gain on settlement of payables	0	9,600	183,768	0
Total Other Expense	-134,155	-241,258	-665,106	-998,924
Net Loss	($1,760,121)	($1,669,676)	($5,587,612)	($5,751,194)
Net Loss Per Share - Basic and Diluted	($0.05)	($0.08)	($0.22)	($0.35)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	35,107,957	20,237,689	25,538,075	16,526,793

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficiency) (USD $)	Total	Cash	Common Stock and Warrants	Shares and warrant issued as debt discount in connection with notes payable	Shares and warrants issued in exchange of notes payable and accrued interest	Shares issued as debt discount in connection with notes payable	Leasehold Improvements	Common Stock	Common Stock	Common Stock	Common Stock	Common Stock	Additional paid-in capital	Additional paid-in capital	Additional paid-in capital	Additional paid-in capital	Additional paid-in capital	Additional paid-in capital	Accumulated deficit	Accumulated deficit	Accumulated deficit	Accumulated deficit	Accumulated deficit	Accumulated deficit	Treasury Stock	Treasury Stock	Treasury Stock	Treasury Stock	Treasury Stock	Treasury Stock
			Cash						Shares and warrant issued as debt discount in connection with notes payable	Shares and warrants issued in exchange of notes payable and accrued interest	Shares issued as debt discount in connection with notes payable	Leasehold Improvements		Cash	Shares and warrant issued as debt discount in connection with notes payable	Shares and warrants issued in exchange of notes payable and accrued interest	Shares issued as debt discount in connection with notes payable	Leasehold Improvements		Cash	Shares and warrant issued as debt discount in connection with notes payable	Shares and warrants issued in exchange of notes payable and accrued interest	Shares issued as debt discount in connection with notes payable	Leasehold Improvements		Cash	Shares and warrant issued as debt discount in connection with notes payable	Shares and warrants issued in exchange of notes payable and accrued interest	Shares issued as debt discount in connection with notes payable	Leasehold Improvements
Beginning Balance at Dec. 31, 2012	($5,141,693)							$15,443					$8,936,084						($14,061,220)						($32,000)
Beginning Balance (in shares) at Dec. 31, 2012								15,443,484																	-558,621
Shares and warrants issued for cash		905,000	841	573,769	417,681				339	819				904,159	573,430	416,862				0	0	0				0	0	0
Shares and warrants issued for cash (in shares)			840,589						338,750	818,495																0	0	0
Shares issued in satisfaction of accrued services	213,000							266					212,734
Shares issued in satisfaction of accrued services (in shares)								266,250
Shares issued in satisfaction of accrued consulting services																			0						0
Shares issued in satisfaction of accrued consulting services (in shares)																									0
Warrant modification in connection with extension of notes payable	214,912							0					214,912						0						0
Waiver of previously accrued executive salary and bonus	565,000							0					565,000						0						0
Exercise of warrants for purchase of common stock	505,809							1,686					504,123						0						0
Exercise of warrants for purchase of common stock (in shares)								1,686,029																	0
Beneficial conversion features related to convertible notes payable	0
Stock-based compensation: shares of common stock	138,055							239					137,816						0						0
Stock-based compensation: shares of common stock (in shares)								239,537																	0
Stock-based compensation: options and warrants	674,592							0					674,592						0						0
Impact of share rounding as a result of reverse stock split								39																	0
Net loss	-5,751,194							0					0						-5,751,194
Ending Balance at Dec. 31, 2013	-6,685,069							19,633					13,139,712						-19,812,414						-32,000
Ending Balance (in shares) at Dec. 31, 2013								19,633,173																	-558,621
Shares and warrants issued for cash		2,605,000	8,672		343,026	249,800	71,050			1,101	1,000	284		2,596,328		341,925	248,800	70,766		0		0	0	0		0		0	0	0
Shares and warrants issued for cash (in shares)			8,671,983							1,101,453	1,000,000	284,200														0		0	0	0
Conversion of notes payable and accrued interest into common stock	359,711							1,785					357,926						0						0
Conversion of notes payable and accrued interest into common stock (in shares)								1,784,777																	0
Shares issued in satisfaction of accrued consulting services	140,000							595					139,405						0						0
Shares issued in satisfaction of accrued consulting services (in shares)								595,455																	0
Warrant modification in connection with extension of notes payable	50,035							0					50,035						0						0
Exercise of warrants for purchase of common stock	113,000							377					112,623						0						0
Exercise of warrants for purchase of common stock (in shares)								376,667																	0
Beneficial conversion features related to convertible notes payable	92,370							0					92,370						0						0
Stock-based compensation: shares of common stock	300,837							1,065					299,772						0						0
Stock-based compensation: shares of common stock (in shares)								1,064,092																	0
Stock-based compensation: options and warrants	1,059,459							0					1,059,459						0						0
Net loss	-5,587,612							0					0						-5,587,612						0
Ending Balance at Dec. 31, 2014	-6,888,393							34,512					18,509,121						-25,400,026						-32,000
Ending Balance (in shares) at Dec. 31, 2014								34,511,800																	-558,621
Shares and warrants issued for cash	801,000		2,703											798,297						0						0
Shares and warrants issued for cash (in shares)			2,703,333																							0
Conversion of notes payable and accrued interest into common stock	55,984							222					55,762						0						0
Conversion of notes payable and accrued interest into common stock (in shares)								222,245																	0
Shares issued in satisfaction of accrued services	8,481							19					8,462						0						0
Shares issued in satisfaction of accrued services (in shares)								18,847																	0
Warrant modification in connection with extension of notes payable	5,900							0					5,900						0						0
Exercise of warrants for purchase of common stock	0
Beneficial conversion features related to convertible notes payable	10,690							0					10,690						0						0
Stock-based compensation: shares of common stock	76,647							294					76,353						0						0
Stock-based compensation: shares of common stock (in shares)								293,948																	0
Stock-based compensation: options and warrants	294,520							0					294,520						0						0
Net loss	-1,760,121							0					0						-1,760,121						0
Ending Balance at Mar. 31, 2015	($7,395,292)							$37,750					$19,759,105						($27,160,147)						($32,000)
Ending Balance (in shares) at Mar. 31, 2015								37,750,173																	-558,621

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net loss	($1,760,121)	($1,669,676)	($5,587,612)	($5,751,194)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	69,515	98,505	464,470	405,531
Accretion of interest expense			24,934	5,066
Depreciation and amortization	39,613	25,517	96,685	104,811
Loss on sale of property and equipment	0	1,009	1,009	0
Stock-based compensation	371,167	373,499	1,360,296	812,647
Loss on extinguishment of note payables, net	0	49,094	49,094	7,200
Gain on settlement of payables	0	-9,600	-183,768	0
Inventory write-down			15,407	0
Warrant modification expense	0	30,128	50,035	214,912
Warrant issued in connection with note payable			0	9,400
Changes in operating assets and liabilities:
Inventories	18	61	613	-5,481
Prepaid expenses and other current assets	-11,868	11,686	11,219	-2,306
Security deposit			-45,900	0
Accounts payable	80,534	-59,380	-234,563	498,541
Accrued interest, expenses and other current liabilities	489,831	192,429	585,881	1,028,469
Deferred revenues	46,533	150,000	164,349	0
Total Adjustments	1,085,343	862,948	2,359,761	3,078,790
Net Cash Used In Operating Activities	-674,778	-806,728	-3,227,851	-2,672,404
Cash Flows From Investing Activities
Purchases of property and equipment	-92,169	0	-168,376	-11,160
Proceeds from sale of property and equipment	0	980	980	0
License maintenance costs	-75,000	0
Net Cash (Used In) Provided By Investing Activities	-167,169	980	-167,396	-11,160
Cash Flows From Financing Activities
Proceeds from notes payable	30,000	140,000	795,000	1,454,000
Repayments of notes payable	0	-25,000	-202,063	-5,500
Advances from officer	125,070	0	58,054	144,285
Repayment of advances from officer	-60,055	-24,990	-83,044	-119,295
Proceeds from exercise of warrants	0	80,000	113,000	505,809
Sales of common stock and warrants for cash	801,000	545,000	2,605,000	905,000
Net Cash Provided By Financing Activities	896,015	715,010	3,285,947	2,884,299
Net Increase (Decrease) In Cash	54,068	-90,738	-109,300	200,735
Cash - Beginning	91,798	201,098	201,098	363
Cash - Ending	145,866	110,360	91,798	201,098
Cash paid during the period for:
Interest	36,540	16,804	127,112	62,346
Non-cash investing and financing activities:
Shares and warrants issued in exchange for notes payable and accrued interest	0	343,026
Conversion of notes payable and accrued interest into common stock	55,984	0	359,711	0
Recharacterization of accrued interest as principal with note payable reissuance			108,059	68,100
Beneficial conversion features set up as debt discount	10,690	0	92,370	0
Waiver of previously accrued executive salary and bonus			0	565,000
Accrued purchases of property and equipment			258,774	0
Change in accrued liabilities associated with Accrued purchases of property and equipment	64,276	0
Payments for previously accrued property and equipment	-91,352	0
Shares Issued in Connection with Notes Payable Extension
Non-cash investing and financing activities:
Shares issued	5,900	0	249,800	564,369
Shares Issued in Satisfaction of Accrued Interest
Non-cash investing and financing activities:
Shares issued			0	213,000
Shares issued in satisfaction of accrued interest
Non-cash investing and financing activities:
Shares issued			343,026	417,681
Shares and warrant issued to satisfy lease obligation and leasehold improvements
Non-cash investing and financing activities:
Shares issued			71,050	0
Shares issued in satisfaction of accrued consulting services
Non-cash investing and financing activities:
Shares issued	$8,481	$0	$140,000	$0

Business_Organization_Nature_o

Business Organization, Nature of Operations and Basis of Presentation	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Business Organization and Nature of Operations	Note 1 – Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization and Nature of Operations
	BioRestorative Therapies, Inc. (and including its subsidiaries, “BRT” or the “Company”) develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells designed for personal medical applications. BRT’s website is at www.biorestorative.com. BRT is currently pursuing a Disc/Spine Program. Its lead cell therapy candidate, brtxDISC™ (Disc Implanted Stem Cells), is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. The product is intended to be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRT is also engaging in research efforts with respect to a platform technology utilizing brown adipose (fat) for therapeutic purposes and has labeled this initiative its ThermoStem® Program. It is a pre-clinical cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue and is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. BRT has developed an ingredient derived from human adult stem cells, which can be used by third party companies in the development of their own skin care products. The ingredient was developed pursuant to BRT’s brtx-C Cosmetic Program. BRT’s Stem Pearls® brand offers plant stem cell-based cosmetic skincare products that are available for purchase online at www.stempearls.com.	BioRestorative Therapies, Inc. has two wholly-owned subsidiaries, Stem Pearls, LLC (“Stem Pearls”) and Stem Cell Cayman Ltd. (“Cayman”), which the Company formed in the Cayman Islands (collectively, “BRT” or the “Company”). BRT develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells designed for personal medical applications. BRT’s website is at www.biorestorative.com. BRT is currently pursuing a Disc/Spine Program. Its lead cell therapy candidate, brtxDISC™ (Disc Implanted Stem Cells), is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. The product is intended to be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRT is also engaging in research efforts with respect to a platform technology utilizing brown adipose (fat) for therapeutic purposes and has labeled this initiative its ThermoStem® Program. It is a pre-clinical cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue and is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans." BRT has developed an ingredient derived from human adult stem cells, which can be used by third party companies in the development of their own skin care products. The ingredient was developed pursuant to BRT’s “brtx-C Cosmetic Program”. BRT’s Stem Pearls® brand offers plant stem cell-based cosmetic skincare products that are available for purchase online at  www.stempearls.com.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of March 31, 2015 and for the three months ended March 31, 2015 and 2014. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full year ending December 31, 2015 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2014 and for the year then ended, which are included elsewhere herein this filing.	Effective January 1, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion, dated December 22, 2014 (the “Plan of Conversion”). Pursuant to the Plan of Conversion, the Company also adopted new bylaws, which became effective on January 1, 2015.
	Effective January 1, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion, dated December 22, 2014 (the “Plan of Conversion”). Pursuant to the Plan of Conversion, the Company also adopted new bylaws, which became effective on January 1, 2015.	Effective April 15, 2013, pursuant to authority granted by the stockholders to the Board of Directors of the Company, the Company implemented a 1-for-50 reverse split of the Company’s issued and outstanding common stock (the “Reverse Split”) and a reduction in the number of shares of common stock authorized to be issued by the Company from 1,500,000,000 to 100,000,000. All share and per share information in these consolidated financial statements has been retroactively adjusted to reflect the Reverse Split. See Note 10 – Stockholders’ Deficiency for additional details regarding the Company’s authorized capital.

Going_Concern_and_Managements_

Going Concern and Management's Plans	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Development Stage Enterprises [Abstract]
Going Concern and Management Plans	Note 2 – Going Concern and Management’s Plans	Note 2 – Going Concern and Management’s Plans
	As of March 31, 2015, the Company had a working capital deficiency and a stockholders’ deficiency of $8,741,867 and $7,395,292, respectively. During the three months ended March 31, 2015 and 2014, the Company incurred net losses of $1,760,121 and $1,669,676, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.	As of December 31, 2014, the Company had a working capital deficiency and a stockholders’ deficiency of $8,410,686 and $6,888,393, respectively. During the years ended December 31, 2014 and 2013, the Company incurred net losses of $5,587,612 and $5,751,194, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	Despite recent revenue generated from specific research and development contracts, the Company's primary source of operating funds since inception has been, and will continue to be for the foreseeable future, equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis and, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.	Despite recent revenue generated from specific research and development contracts, the Company's primary source of operating funds since inception has been, and will continue to be for the foreseeable future, equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis and, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.
	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.	The accompanying consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.
	Subsequent to March 31, 2015, (a) the Company has raised an aggregate of $200,000 and $100,000 through equity financing and debt financing, respectively, and (b) $307,873 and $26,501 of debt and accrued interest, respectively, has been exchanged for or converted into common stock. As a result, the Company expects to be able to fund its operations through June 2015. While there can be no assurance that it will be successful, the Company is in active negotiations to raise additional capital. See Note 8 – Subsequent Events for additional details.	Subsequent to December 31, 2014, (a) the Company has raised an aggregate of $801,000 and $30,000 through equity financing and debt financing, respectively, (b) the Company has received research and development payments of $227,234 and (c) $50,000 and $5,984 of debt and accrued interest, respectively, has been converted into common stock. As a result, the Company expects to be able to fund its operations through April 2015. While there can be no assurance that it will be successful, the Company is in active negotiations to raise additional capital. As of the filing date of this report, the Company has notes payable with an aggregate principal balance of $5,000 which are either past due or payable on demand. The Company is currently in the process of negotiating extensions or discussing conversions to equity with respect to these notes. However, there can be no assurance that the Company will be successful in extending or converting these notes. See Note 11– Subsequent Events for additional details.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies					Note 3 – Summary of Significant Accounting Policies
	Principles of Consolidation					Principles of Consolidation
	The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation.					The consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
	Use of Estimates					Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s equity securities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.					The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s equity securities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
	Concentrations and Credit Risk					Concentrations and Credit Risk
	As of March 31, 2015, 76% of the face value of the Company’s outstanding notes payable were sourced from a single entity (the “Bermuda Lender”). As of the date of filing, the maturity date associated with these notes was June 30, 2015. See Note 5 – Notes Payable and Note 8 – Subsequent Events – Note Payable for additional discussion of the Bermuda Lender.					As of December 31, 2014, 75% of the face value of the Company’s outstanding notes payable were sourced from a single entity (the “Bermuda Lender”) and the maturity dates associated with these notes range from May 7, 2015 to June 30, 2015. See Note 7 – Notes Payable for additional discussion of the Bermuda Lender.
	Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three months ended March 31, 2015. See Revenue Recognition – Research and Development Agreements below.					Two pharmaceutical clients comprised substantially all of the Company’s revenue during the year ended December 31, 2014. See Revenue Recognition – Research and Development Agreements below.
	Revenue Recognition					Cash
	Research and Development Agreements					The Company maintains cash in bank accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to be negligible.
	The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables.					Inventories
	During the three months ended March 31, 2015, in connection with a March 19, 2014 research and development agreement with a Japanese pharmaceutical company, the Company received $50,000 upon achievement of a specified deliverable (milestone method). Through March 31, 2015, $200,000 had been received under the agreement and recognized as revenue. On February 11, 2015, the term of the agreement was extended by three months to June 19, 2015.					The Company maintains finished goods inventories, consisting of Stem Pearls skincare products, which are available for sale. Inventories are stated at the lower of cost or market. Cost is determined by the first-in, first-out method.
	During the three months ended March 31, 2015, in connection with a March 24, 2014 research and development agreement with a U.S. pharmaceutical company, the Company received the third and fourth of four quarterly payments in the aggregate amount of $177,234. Through March 31, 2015, $605,359 had been received and $210,882 was recorded as deferred revenues on the condensed consolidated balance sheet.					The Company periodically reviews for slow-moving, excess or obsolete inventories. Products that are determined to be obsolete, if any, are written down to net realizable value. During the year ended December 31, 2014, the Company recorded an inventory write-down of $15,407.
	During the three months ended March 31, 2015, the Company recognized revenue related to research and development agreements of $180,702. The Company did not recognize any revenue related to research and development agreements during the three months ended March 31, 2014.					Property and Equipment
	Other					Property and equipment are stated at cost, net of accumulated depreciation which is recorded commencing at the in-service date using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 3 to 5 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred.
	The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.					Intangible Assets
	For the three months ended March 31, 2015 and 2014, the Company recognized revenue related to sales of Stem Pearls® skincare products of $200 and $375, respectively. In connection with its January 27, 2012 sublicense agreement with a stem cell treatment company, for the three months ended March 31, 2015 and 2014, the Company recognized royalty revenue of $4,000 and $0, respectively.					Intangible assets are comprised of trademarks and licenses with original estimated useful lives of 10 and 17.7 years (20 year life of underlying patents which the Company is licensing, less 2.3 years elapsed since the application date of the respective patents), respectively. Once placed into service, the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis.
	Net Loss Per Common Share					Impairment of Long-lived Assets
	Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes.					The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company has not identified any such impairment losses.
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:					Revenue Recognition
		March 31,
		2015		2014		Research and Development Agreements
	Options		16,184,000		7,783,000
	Warrants		9,099,516		5,325,751	The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables.
	Convertible instruments		678,806		1,519,015
	Total potentially dilutive shares		25,962,322		14,627,766	On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $150,000 received at commencement (straight-line method);  (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). As of December 31, 2014, the initial $150,000 payment had been received and $34,281 remained in deferred revenues on the consolidated balance sheet. On February 11, 2015, the term of the agreement was extended by three months to June 19, 2015.
	Stock-Based Compensation					On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments (all of which are being recognized pursuant to the straight-line method), subject to acceleration upon achieving a specified deliverable. As of December 31, 2014, the initial $250,000 payment and the first two quarterly payments of $89,063 related to (2) above had been received and $130,068 was recorded as deferred revenues on the consolidated balance sheet.
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTCQB. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.					During the year ended December 31, 2014, the Company recognized revenue related to research and development agreements of $413,777. The Company did not recognize any revenue related to research and development agreements during the year ended December 31, 2013.
	Subsequent Events					Other
	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.					The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.
						For the years ended December 31, 2014 and  2013, the Company recognized revenue related to sales of Stem Pearls® skincare products of $2,219 and $1,680, respectively.
						Income Taxes
						The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.
						The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
						Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of December 31, 2014 and 2013. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.
						The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.
						Net Loss Per Common Share
						Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes.
						The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
							December 31,
							2014		2013
						Options		15,584,000		5,043,000
						Warrants		8,248,683		4,795,890
						Convertible notes		653,885		1,063,380
						Total potentially dilutive shares		24,486,568		10,902,270
						Stock-Based Compensation
						The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTC Bulletin Board. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
						Advertising
						Advertising costs are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred advertising costs of $15,280 and $25,748, respectively. Advertising expense is reflected in marketing and promotion expenses in the consolidated statements of operations.
						Research and Development
						Research and development expenses are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred research and development expenses of $1,430,614 and $1,594,054, respectively.
						Reclassifications
						Certain prior period amounts have been reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the previously reported net loss.
						Fair Value of Financial Instruments
						The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
						ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
						Level 1 — quoted prices in active markets for identical assets or liabilities
						Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
						Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)
						The carrying amounts of cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. The carrying amounts of our short term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, taken together with other features such as concurrent issuance of warrants, are comparable to rates of returns for instruments of similar credit risk.
						Convertible Instruments
						GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP.
						When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
						Subsequent Events
					The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed in Note 11.
					Recently Issued Accounting Pronouncements
					In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition (“ASC 605”) and most industry-specific guidance throughout ASC 605. The standard requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.
					In June 2014, the FASB issued ASU No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation,” (“ASU 2014-10”). ASU 2014-10 removes the definition of a development stage entity from the Master Glossary of the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company adopted ASU 2014-10 during the year ended December 31, 2014 which resulted in the removal of previously required development stage disclosures. The Company’s planned principal operations are to develop technology using cell and tissue therapy protocols, primarily involving adult stem cells, allowing patients to undergo cellular-based treatments. The Company has established a new laboratory facility and is seeking to increase its capabilities for the further development of possible cellular-based treatment protocols, stem cell-related intellectual property and research applications. The Company’s activities are subject to significant risks and uncertainties, which are detailed in Note 2 – Going Concern and Management’s Plans.
					In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of ASU 2014-12 will have a material impact on its consolidated financial statements.
					In August 2014, the FASB issued ASU No. 2014-15,”Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company elected to adopt ASU 2014-15. Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 2 – Going Concern and Management’s Plans.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 – Property and Equipment
	Property and equipment include the following:
		December 31,
		2014		2013
	Office equipment	$	8,466	$	7,670
	Medical equipment		359,248		129,461
	Furniture and fixtures		113,874		19,322
	Computer software and equipment		66,458		20,169
	Leasehold Improvements		103,582		-
			651,628		176,622
	Less: accumulated depreciation		-157,772		-141,054
	Property and equipment, net	$	493,856	$	35,568
	Depreciation expense amounted to $26,872 and $34,999 for the years ended December 31, 2014 and 2013, respectively. Depreciation expense is reflected in general and administrative expenses in the consolidated statements of operations.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2014
Disclosure Intangible Assets [Abstract]
Intangible Assets	Note 5 – Intangible Assets
	Intangible assets consist of the following:
		Patents and				Accumulated
		Trademarks		Licenses		Amortization		Total
	Balance as of January 1, 2013	$	3,676	$	1,226,500	$	-52,819	$	1,177,357
	Amortization expense		-		-		-69,812		-69,812
	Balance as of December 31, 2013	$	3,676	$	1,226,500	$	-122,631	$	1,107,545
	Amortization expense		-		-		-69,813		-69,813
	Balance as of December 31, 2014	$	3,676	$	1,226,500	$	-192,444	$	1,037,732
	Weighted average remaining amortization period at December 31, 2014 in years		6		14.9
	Amortization of intangible assets consists of the following:
		Patents and				Accumulated
		Trademarks		Licenses		Amortization
	Balance as of January 1, 2013	$	736	$	52,083	$	52,819
	Amortization expense		368		69,444		69,812
	Balance as of December 31, 2013	$	1,104	$	121,527	$	122,631
	Amortization expense		368		69,445		69,813
	Balance as of December 31, 2014	$	1,472	$	190,972	$	192,444
	Amortization expense is reflected in general and administrative expenses in the consolidated statements of operations. Based upon the current intangible assets as of December 31, 2014, amortization expense is projected to be approximately $70,000 per annum through 2029.
	On January 27, 2012, the Company entered into a license agreement with a stem cell treatment company (“SCTC”) (as amended on March 21, 2012, the “SCTC Agreement”). On April 6, 2012 (the “Closing Date”), the Company and SCTC closed on the SCTC Agreement. Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from SCTC to utilize or sublicense a certain medical device patent (pending) for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or sublicense a certain method for culturing cells. The SCTC Agreement provides that the Company must achieve certain milestones. As of December 31, 2014, the Company had not met any the milestones provided for in the SCTC Agreement to be fulfilled by April 6, 2014; however, it still had the ability to pay  $75,000 by April 6, 2015 in order to retain the exclusivity of the license. On March 5, 2015, the Company made the $75,000 cash payment to retain the exclusivity of the license. Pursuant to the license agreement with SCTC, unless certain milestones are satisfied, the Company will be required to pay to SCTC minimum amounts of between $225,000 and $475,000 during the period from April 2017 to April 2019 in order to maintain its exclusive rights with regard to the disc/spine technology.
	The SCTC Agreement also provides for an exclusive, royalty-bearing sublicense of certain of the licensed technology to SCTC for use for orthopedic purposes and a non-exclusive, royalty-bearing sublicense of certain of the licensed technology to SCTC for use (1) at a single facility in the Cayman Islands (or, under certain circumstances, at a different non-U.S. facility), and (2) at U.S. facilities (in accordance with protocols established by the Company), if and only if, upon resolution of a Food and Drug Administration (“FDA”) action, SCTC has the legal right to exploit the technology in the U.S. and the Company does not yet have such legal right. Further, the SCTC Agreement provides that SCTC will furnish certain training, assistance and consultation services with regard to the licensed technology. In addition, the Company had agreed to reimburse SCTC for 25% of its legal fees associated with what had been a pending court action with the FDA, subject to a maximum of $4,500 per month and $100,000 in the aggregate. In 2012, the District Court ruled in favor of the FDA, but SCTC appealed the decision. In February 2014, the United States Court of Appeals for the D.C. Circuit affirmed the District Court’s ruling, concluding that the FDA has the authority to regulate certain autologous stem cell procedures and that SCTC’s stem cell mixture meets the definition of drug and not HCT/P since it was more than minimally manipulated. SCTC has indicated that it does not intend to appeal the decision to the Supreme Court. While this decision is specific to SCTC’s procedures and mixture, it indicates that stem cells, even when used in an autologous context, may be regulated as drugs, particularly when mixed with other substances or in other ways that may be considered to be more than minimally manipulated. The Company is proceeding with the FDA approval process for its initiatives as discussed above.
	Pursuant to the SCTC Agreement, on the Closing Date, the Company made a payment to SCTC consisting of a license fee of $1,000,000, net of a sublicensing fee of $10,000, which SCTC owed to the Company (which was recorded as revenue in the consolidated statements of operations), and issued to SCTC a warrant for the purchase of 1,000,000 shares of common stock of the Company (the “SCTC Warrant”). The vesting of the SCTC Warrant was divided into three tranches. The first tranche to purchase 300,000 shares of common stock was immediately exercisable. The exercise of the second and third tranches to purchase 350,000 shares of common stock each is subject to specified performance criteria. The exercise price for the initial tranche is $1.50 per share and the exercise price for the second and third tranches is the greater of $1.50 per share or the then fair market value of the common stock, as defined in the SCTC Agreement. The initial tranche had a grant date value of $226,500 using the Black-Scholes model, which was recognized immediately. The Company recorded the $1,000,000 cash payment and the $226,500 value of the first tranche of the warrant as an intangible asset with an original estimated useful life of 17.7 years (20 year life of the underlying pending patent less 2.3 years since patent application).
	The Company has not made an accounting entry related to the second and third tranches as it is not currently estimable when the specified performance criteria will be met. When, and if, the second and third tranches of the SCTC Warrant vest (or when the timing of vesting becomes estimable), the grant date value of these tranches will be added to the value of the intangible asset after calculating the grant date values using the Black-Scholes option pricing model using the final exercise prices as inputs to the model.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities					Note 6 – Accrued Expenses and Other Current Liabilities
	Accrued expenses and other current liabilities are comprised of the following:					Accrued expenses and other current liabilities are comprised of the following:
		March 31,		December 31,			December 31,
		2015		2014			2014		2013
		(unaudited)
						Credit card payable	$	4,739	$	6,000
	Credit card payable	$	3,971	$	4,739	Accrued payroll and payroll taxes		679,277		672,535
	Accrued payroll and payroll taxes		777,757		679,277	Accrued purchases of property and equipment		174,801		-
	Accrued purchases of property and equipment		74,587		174,801	Accrued research and development expenses		292,395		229,276
	Accrued research and development expenses		316,175		292,395	Accrued general and administrative expenses		315,294		266,541
	Accrued general and administrative expenses		679,069		315,294	Deferred rent		-		2,310
	Deferred rent		33,000		-	Total	$	1,466,506	$	1,176,662
	Total	$	1,884,559	$	1,466,506
						During the year ended December 31, 2014, the Company received an aggregate of $58,054 in non-interest bearing advances from a director, an officer and a family member of the same officer and made aggregate repayments of $83,044 (inclusive of the $24,990 outstanding balance as of December 31, 2013 discussed below), such that the Company had no remaining liability with regard to these advances as of December 31, 2014. During the year ended December 31, 2013, the Company received an aggregate of $144,285 in advances from a director, an officer and a family member of the same officer and made aggregate repayments of $119,295, such that the Company had a liability of $24,990 with regard to these advances as of December 31, 2013.
	During the three months ended March 31, 2015, the Company received an aggregate of $125,070 in non-interest bearing advances from an officer and made aggregate repayments of $60,055, such that the Company has $65,015 remaining liability with regard to these advances as of March 31, 2015. During the three months ended March 31, 2014, the Company made aggregate repayments to a director and a family member of an officer of $24,990, such that the Company had no remaining liability at March 31, 2014.

Notes_Payable

Notes Payable	3 Months Ended													12 Months Ended
	Mar. 31, 2015													Dec. 31, 2014
Notes Payable [Abstract]
Notes Payable	Note 5 – Notes Payable													Note 7 – Notes Payable
	A summary of the notes payable activity during the three months ended March 31, 2015 is presented below:													A summary of the notes payable activity during the years ended December 31, 2014 and 2013 is presented below:
			Bermuda		Convertible			Other		Debt
			Lender		Notes			Notes		Discount		Total				Bermuda		Convertible			Other			Debt
																Lender		Notes			Notes			Discount			Total
	Outstanding, December 31, 2014		$	4,410,937	$	175,000		$	1,265,559	$	-113,257	$	5,738,239
	Issuance			-		30,000			-		-		30,000	Outstanding, December 31, 2012		$	3,550,000	$	-		$	1,082,185		$	-76,719		$	4,555,466
	Conversion to equity			-		-50,000			-		-		-50,000	Issuances			450,000		281,000	[1]		733,000			-			1,464,000
	Recognition of debt discount			-		-			-		-16,590		-16,590	Conversion of accrued interest			-		-			68,100			-			68,100
	Amortization of debt discount			-		-			-		69,515		69,515	Exchanges for equity			-		-			-404,285			-			-404,285
	Outstanding, March 31, 2015		$	4,410,937	$	155,000	[1]	$	1,265,559	$	-60,332	$	5,771,164	Repayments			-		-			-5,500			-			-5,500
														Recognition of debt discount			-		-			-			-574,369	[1]		-574,369
		[1]	As of March 31, 2015, convertible notes with an aggregate principal balance of $155,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.											Amortization of debt discount			-		-			-			405,531			405,531
														Accretion of interest expense			-		-			-			5,066	[1]		5,066
	Bermuda Lender													Outstanding, December 31, 2013		$	4,000,000	$	281,000		$	1,473,500		$	-240,491		$	5,514,009
														Issuances			500,000		300,000	[1]		-			-			800,000
	As of March 31, 2015, the Bermuda Lender is a related party as a result of the size of its ownership interest in the Company's common stock.													Exchanges for equity			-		-71,000			-203,000			-			-274,000
														Conversions to equity			-		-342,500			-			-			-342,500
	See Note 3 – Summary of Significant Accounting Policies – Concentrations and Credit Risk and Note 8 – Subsequent Events – Note Payable for additional discussion of the Bermuda Lender.													Repayments			-89,063		-			-113,000			-			-202,063
														Recognition of debt discount			-		-			-			-347,170	[1]		-347,170
	Convertible Notes													Amortization of debt discount			-		-			-			464,470			464,470
														Recharacterization of accrued interest as principal			-		-			108,059	[3]		-			108,059
	On January 25, 2015, the Company issued a six-month convertible note with a principal amount of $30,000 which bears interest at a rate of 12% per annum payable upon maturity. The convertible note is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at the greater of (a) 55% of the fair value of the Company’s stock or (b) $0.10 per share.													Accretion of interest expense			-		15,000	[2]		-			9,934	[1]		24,934
														Settlement of accreted interest			-		-7,500	[2]		-			-			-7,500
	On February 17, 2015, the Company elected to convert a convertible note with a principal balance of $50,000 and accrued interest of $5,984 into 222,245 shares of common stock at a conversion price of $0.25 per share.													Outstanding, December 31, 2014		$	4,410,937	$	175,000	[4]	$	1,265,559		$	-113,257		$	5,738,239
	During the three months ended March 31, 2015, the contingently adjustable conversion ratio associated with a certain convertible note was resolved. The Company estimated the intrinsic value of the embedded conversion option based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the three months ended March 31, 2015, the Company recognized $10,690 of intrinsic value related to the beneficial conversion feature as debt discount which was immediately amortized.														[1]	During the years ended December 31, 2014 and 2013, notes with an aggregate principal amounts of $30,000 and $60,000, respectively, bear no interest and were issued for cash consideration of $25,000 and $50,000, respectively. The differences between the principal amounts of the notes and the cash received of $5,000 and $10,000, respectively, were recorded as debt discount and amortized to interest expense over the term of the notes.
															[2]	During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to June 10, 2014, the aggregate principal balance of the notes was increased from $90,000 to $105,000. The aggregate $15,000 of principal increases was accreted as interest expense. During the year ended December 31, 2014, $7,500 of the principal increases was settled by the conversion of a convertible note with a maturity date of January 8, 2014 and original principal balance of $30,000 into shares of the Company's common stock.
															[3]	During the year ended December 31, 2014, in connection with the extension of certain notes payable with maturity dates ranging from of August 8, 2013 to March 1, 2014, an aggregate $108,059 of accrued interest was added to the aggregate principal balance of the notes, increasing the aggregate principal balance from $752,500 to $860,559.
															[4]	As of December 31, 2014, convertible notes with an aggregate principal balance of $175,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.
														Bermuda Lender
														On March 26, 2013, Cayman borrowed $450,000 from the Bermuda Lender, which was combined with the already outstanding $3,550,000 of previous borrowings from the Bermuda Lender into a new $4,000,000 zero coupon note (the “$4,000,000 Bermuda Lender Note”) which matured on July 31, 2014. In consideration of the additional $450,000 loan, the waiver of accrued and unpaid interest of $213,000, and an extension of the maturity date of the outstanding loan, the Company issued to the Bermuda Lender 600,000 shares of common stock (valued at $480,000) and a five year warrant to purchase 400,000 shares of common stock at an exercise price of $2.50 per share (valued at $250,000). After determining that 266,250 shares of common stock (of the 600,000 shares issued) were, in effect, used to settle the aggregate $213,000 accrued and unpaid interest, the Company determined that the relative fair value of the remaining equity securities issued was $457,826, which amount was recorded as a debt discount and was amortized via the interest method over the sixteen month term of the $4,000,000 Bermuda Lender Note in accordance with ASC 470-60. The effective annual interest rate of the $4,000,000 Bermuda Lender Note is 11%.
														On May 8, 2014, Cayman borrowed an additional $500,000 from the Bermuda Lender and issued to the Bermuda Lender a one-year note payable in the principal amount of $500,000 which bears interest at 15% per annum payable at maturity. The note also provides for the mandatory prepayment of the principal amount to the extent of any monies received by the Company pursuant to the research and development agreements discussed in Note 3 – Summary of Significant Accounting Policies – Revenue Recognition – Research and Development Agreements. Interest on the entire principal amount of the note is payable until such time as the principal amount is paid in full. On July 15, 2014, the Company received $89,063 pursuant to the research and development agreements which triggered a mandatory principal prepayment of $89,063. See Note 11 – Subsequent Events for details regarding monies received pursuant to the research and development agreements.
														On August 13, 2014, Cayman and the Bermuda Lender agreed to extend the maturity date of the $4,000,000 Bermuda Lender Note from July 31, 2014 to December 31, 2014. In consideration of the extension, the Company issued to the Bermuda Lender 550,000 shares of common stock. The $121,000 fair value of the common stock was recorded as debt discount and was amortized over the remaining term of the $4,000,000 Bermuda Lender Note.
														On December 31, 2014, Cayman and the Bermuda Lender agreed to further extend the maturity date of the $4,000,000 Bermuda Lender Note from December 31, 2014 to June 30, 2015. In consideration of the extension, the Company issued to the Bermuda Lender 450,000 shares of common stock. The $99,000 fair value of the common stock was recorded as debt discount and will be amortized over the remaining term of the $4,000,000 Bermuda Lender Note.
														As of December 31, 2014, the Bermuda Lender is a related party as a result of the size of its ownership interest in the Company's common stock.
														Convertible Notes
														Between August 8, 2013 and December 18, 2013, the Company issued convertible notes with an aggregate principal amount of $281,000, for cash consideration of $271,000 (convertible notes with an aggregate principal amount of $60,000 bear no interest and were issued for cash consideration of $50,000 and the $10,000 of interest, was recorded as debt discount and will be amortized over the term of the note, resulting in a weighted average effective interest rate of 100%). Convertible notes with an aggregate principal amount of $221,000 bear interest at a rate of 12% per annum payable upon maturity. The convertible notes were initially payable 2-6 months from the date of issuance. Of the $281,000 principal amount of convertible notes, $171,000 are convertible into shares of the Company’s common stock at the election of the Company while $110,000 are convertible into shares of the Company’s common stock at the election of the holder. The convertible notes are convertible during the period beginning five days prior to maturity and ending on the day immediately prior to maturity (the “Note Conversion Period”). The conversion price of the convertible notes is equal to the greater of (a) 55-65% (depending on the specific note) of the fair value of the Company’s common stock or (b) $0.05 per share. As of December 31, 2013, the convertible notes were not convertible. The Company evaluated the conversion options and determined that bifurcation was not necessary in accordance with ASC 815. The beneficial conversion features will be accounted for, if necessary, at the commitment date.
														Between January 17, 2014 and May 2, 2014, the Company issued convertible notes with an aggregate principal amount of $175,000, for cash consideration of $170,000 (a convertible note with a principal amount of $30,000 bears no interest and was issued for cash consideration of $25,000 and the $5,000 difference was recorded as debt discount and was accreted as interest over the term of the note). Convertible notes with an aggregate principal amount of $145,000 bear interest at a rate of 12% per annum payable upon maturity. The convertible notes were initially payable 3-12 months from the date of issuance. Of the $175,000 principal amount of convertible notes, $145,000 is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at the greater of (a) 55%-60% (depending on the particular note) of the fair value of the Company’s stock or (b) $0.05 per share. The remaining $30,000 is convertible into shares of the Company’s common stock at the election of the holder any time after September 10, 2014 at the lesser of (a) $0.50 per share or (b) 65% of the fair value of the Company’s common stock, but with a floor of $0.05 per share.
														Between November 12, 2014 and December 2, 2014, the Company issued convertible notes in the aggregate principal amount of $125,000 which bear interest at a rate of 10% per annum payable on maturity. The convertible notes are payable as follows: (i) $41,667 of aggregate principal and the respective accrued interest on such principal is payable six months from the issuance date (the “First Maturity Date”), (ii) $41,667 of principal and the respective accrued interest on such principal is payable two weeks following the First Maturity Date (the “Second Maturity Date”), and (iii) $41,666 of principal and the respective accrued interest on such principal is payable one month following the First Maturity Date (the “Third Maturity Date”). Each $41,667 and $41,666 of aggregate principal and the respective accrued interest on such principal is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at the greater of (a) 60% of the fair value of the Company’s stock or (b) $0.05 per share. In the event that the Company elects to effect a conversion, during the five day period following the conversion, the holders shall have the right to convert the then outstanding principal amount of the convertible notes, together with accrued and unpaid interest thereon, into shares of the Company’s common stock at a conversion price equal to the conversion price in the Company-effected conversion.
														During the year ended December 31, 2014, the Company elected to convert certain convertible notes with an aggregate principal balance of $225,000 and aggregate accrued interest of $13,565 into an aggregate of 1,202,744 shares of common stock at conversion prices ranging from $0.14 to $0.28 per share.
														During the year ended December 31, 2014, the holders of certain convertible notes elected to convert such convertible notes with an aggregate principal balance of $117,500 and aggregate accrued interest of $3,646 into an aggregate of 582,033 shares of common stock at conversion prices ranging from $0.19 to $0.22 per share.
														During the year ended December 31, 2014, the Company and certain lenders agreed to exchange certain convertible notes with an aggregate principal balance of $71,000, along with accrued and unpaid interest of $4,260, for an aggregate of 246,764 shares of common stock and an immediately vested, two-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.75 per share. The common stock and warrants had an aggregate grant date value of $74,029 and, as a result, the Company recorded a gain on extinguishment of $1,231. The lenders received piggyback registration rights related to the stock and the stock issuable pursuant to the warrants.
														During the year ended December 31, 2014, the contingently adjustable conversion ratios associated with certain convertible notes were resolved. The Company estimated the intrinsic value of the embedded conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the year ended December 31, 2014, the Company recognized $92,370 of intrinsic value related to these beneficial conversion features as debt discount which was immediately amortized.
														Other Notes
														Other notes issued by the Company (“Other Notes”) predominantly bear interest at a rate of 15% per annum payable monthly. As of December 31, 2014, the Other Notes have maturity dates through October 2015.
														The holders of two Other Notes are entitled to five years of royalty payments associated with Cosmetic Revenues, as defined in the notes, ranging from 0.5% to 4.0% of Cosmetic Revenues, depending on the holder and the year the Cosmetic Revenues are earned. The final three years of royalty payments are subject to an annual dollar maximum of $100,000 for one of the noteholders. Given that the Company has not yet generated any Cosmetic Revenues, no royalty payments have been earned.
														In connection with the issuance and extension of Other Notes during the year ended December 31, 2013, the Company issued 5,000 shares of common stock, with a relative fair value of $3,704. In connection with the issuances, five-year warrants to purchase an aggregate of 402,500 shares of common stock at exercise prices ranging from $0.94 to $2.50 per share, with a relative fair value of $112,239, were issued as debt discount to the lenders and amortized over the term of the note.
														In connection with the extension of Other Notes during the year ended December 31, 2014, the Company issued five-year warrants to purchase an aggregate of 190,000 shares of common stock at exercise prices ranging from $0.50 to $0.75 per share, with a grant date fair value of $29,800, as debt discount to the lenders and amortized over the term of the note.
														During the year ended December 31, 2013, the Company and certain lenders agreed to exchange certain Other Notes with an aggregate principal balance of $404,285, along with accrued and unpaid interest of $6,196, for an aggregate of 818,495 shares of common stock and five-year warrants to purchase an aggregate of 45,000 shares of common stock at an exercise price of $1.50 per share. The stock and warrants had an aggregate issuance date value of $417,681 and, as a result, the Company recorded a loss on extinguishment of $7,200. The lenders received piggyback registration rights related to the stock and the stock issuable pursuant to the warrants.
														During the year ended December 31, 2014, the Company and certain lenders agreed to exchange certain Other Notes with an aggregate principal balance of $203,000, along with accrued and unpaid interest of $15,672, for an aggregate of 854,689 shares of common stock and an immediately vested, two-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.75 per share. The common stock and warrants had an aggregate grant date value of $268,997 and, as a result, the Company recorded a loss on extinguishment of $50,325. The lenders received piggyback registration rights related to the stock and the stock issuable pursuant to the warrants.
														During the year ended December 31, 2014, the Company repaid certain Other Notes with an aggregate principal balance of $113,000 and accrued interest of $11,219.
														See Note 11 – Subsequent Events for additional details regarding notes payable.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Note 8 – Income Taxes
	United States and foreign components of loss before income taxes were as follows:
		For The Years Ended
		December 31,
		2014			2013
	United States	$	-5,223,749		$	-5,328,958
	Foreign		-363,863			-422,236
	Loss before income taxes	$	-5,587,612		$	-5,751,194
	The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:
		For The Years Ended
		December 31,
		2014			2013
	Deferred Tax Assets:
	Net operating loss carryforward	$	4,820,500		$	5,327,000
	Stock-based compensation		1,272,600			907,100
	Accruals		240,700			139,800
	Research & development tax credits		95,500			-
	Other		2,100			2,700
	Gross deferred tax assets		6,431,400			6,376,600
	Deferred Tax Liabilities:
	Fixed assets		-93,200			-
	Intangible assets		-8,100			-3,000
	Gross deferred tax liabilities		-101,300			-3,000
	Net deferred tax assets		6,330,100			6,373,600
	Valuation allowance		-6,330,100			-6,373,600
	Deferred tax asset, net of valuation allowance	$	-		$	-
	Changes in valuation allowance	$	-43,500		$	1,631,300
	The income tax provision (benefit) consists of the following:
		For The Years Ended
		December 31,
		2014			2013
	Federal:
	Current	$	-		$	-
	Deferred		38,921			-1,459,584
	State and local:
	Current		-			-
	Deferred		4,579			-171,716
			43,500			-1,631,300
	Change in valuation allowance		-43,500			1,631,300
	Income tax provision (benefit)	$	-		$	-
	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		For The Years Ended
		December 31,
		2014				2013
	Tax benefit at federal statutory rate		-34	%			-34	%
	State income taxes, net of federal benefit		-4	%			-4	%
	Permanent differences		0.8	%			5.8	%
	Research & development tax credits		-1.8	%			0	%
	Impact of Section 382 limit		41.2	%			0	%
	True-ups and other		-1.4	%			1.6	%
	Change in valuation allowance		-0.8	%			30.6	%
	Effective income tax rate		0	%			0	%
	The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized.
	At December 31, 2014 and 2013, the Company had approximately $12,700,000 and $14,000,000, respectively, of federal and state net operating losses that may be available to offset future taxable income. The net operating loss carry forwards, if not utilized, will expire from 2029 to 2034 for federal purposes. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carry forwards are subject to annual limitations due to greater than 50% ownership changes. The Section 382 limitation that became effective on or about July 2014 has resulted in (a) approximately $5,700,000 of federal NOLs not being realizable; and (b) the reversal of approximately $2,200,000 of net operating loss deferred tax assets.
	The Company files income tax returns in the U.S. federal jurisdiction and the states of Florida and New York, and is subject to examination by the various taxing authorities beginning with the tax years ended December 31, 2011.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies	Note 9 – Commitments and Contingencies
	Operating Lease	Operating Lease
	Rent expense amounted to approximately $35,000 and $11,000 during the three months ended March 31, 2015 and 2014, respectively, which is reflected in general and administrative expenses in the condensed consolidated statements of operations.	Jupiter, Florida Lease
	Litigations, Claims and Assessments	The Company was a party to  a three year lease agreement with respect to premises located at the Alexandria Innovation Center in Jupiter, Florida, which was scheduled to expire on January 31, 2014. No base rent was payable during the initial year and the lease provided for a base monthly rent of $6,234 during the second year and $6,422 during the third year. The Company had the right to lease the premises for an additional three years at the then fair market value rent. The aggregate base rent payable over the lease term was recognized on a straight-line basis.
	In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business.	On February 4, 2014, the Company and the landlord agreed to the surrender of a portion of the leased premises and also extended the term of the lease to July 31, 2014. The amended lease provided for a base rent of $962 per month. The Company and the landlord subsequently agreed to a series of lease extensions, such that the lease ultimately terminated on December 31, 2014.
	In November 2013, an action was commenced against the Company in the Circuit Court of Palm Beach County, Florida by an alleged former consultant. The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009. Pursuant to the action, the plaintiff was seeking to recover an unspecified amount of damages as well as the repayment of the alleged loan with interest, reimbursement for certain out-of-pocket fees and expenses, two weeks vacation pay per year, and the issuance of shares of the Company’s common stock (or alternatively the market value of such securities). On April 27, 2015, the Company and the plaintiff entered into a settlement agreement for an amount which has been accrued as of March 31, 2015.	On February 11, 2014, the Company executed a Facility Use Agreement with the SCTC which permitted the Company to utilize the SCTC’s laboratory facility and one office for research associated with its culturing and medical device license. Payment terms were $3,750 per month through March 31, 2014 and $100 per day for usage beyond that date. The Company ceased using the SCTC’s laboratory facility on March 31, 2014.
	The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.	On August 25, 2014, the Company entered into a lease for 6,800 square feet of space located in Melville, New York (the “Melville Lease”). Late in 2014, the Company relocated its corporate and laboratory operations from Jupiter, Florida to such location. The Melville Lease provides for a term of 63 months from the commencement date (as defined in the Melville Lease) (subject to extension at the option of the Company for a period of five years) and an annual base rental during the initial term ranging between $132,600 and $149,260. Pursuant to the Melville Lease, no rent was payable for the initial four months of the term.
	Employment Agreements	In connection with the Melville Lease, the Company paid the landlord a cash security deposit of $45,900, which is reflected on the consolidated balance sheet as of December 31, 2014. Additionally, in connection with the execution of the Melville Lease, the Company issued to the principals of the landlord an aggregate of 284,200 shares of its common stock and five-year warrants to purchase an aggregate of 142,100 shares of its common stock at an exercise price of $0.50 per share as consideration for: (i) $60,000 towards the leasehold improvements of the leased premises and (ii) $11,050 of prepaid rent for the fifth month of the lease. During the year ended December 31, 2014, the Company has (i) recorded a credit to equity for the $71,050 value of the common stock and warrants, (ii) capitalized $60,000 of leasehold improvements which is included within property and equipment, net on the consolidated balance sheet as of December 31, 2014, and will be amortized over the term of the lease and (iii) recorded prepaid rent of $11,050 within prepaid expenses and other current assets on the consolidated balance sheet as of December 31, 2014, which will be expensed following the fifth month of the lease.
	On February 9, 2015, the Company hired a President for its Disc/Spine Division (“Division President”) pursuant to an at-will employment agreement which entitles him to a specified salary and a discretionary bonus. In the event the Company terminates the Division President without cause, the Division President is entitled to cash severance payments of $150,000 paid over nine months. As additional compensation, the Company granted the Division President a ten-year option to purchase 500,000 shares of common stock at an exercise price of $0.46 per share, pursuant to the Plan. The shares vest over three years on the grant date anniversaries. The grant date value of $200,400 will be recognized proportionate to the vesting period.	Rent expense amounted to $20,380 and $99,175 for the years ended December 31, 2014 and 2013, respectively. Rent expense is reflected in general and administrative expenses in the consolidated statements of operations.
	On March 9, 2015, the Company and its Chief Executive Officer (“CEO”) agreed to extend the term of his employment agreement to December 31, 2017. Pursuant to the employment agreement, the CEO is entitled to receive a salary of $400,000 per annum. The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Company’s Compensation Committee, are satisfied. Pursuant to the employment agreement, in the event that the CEO’s employment is terminated by the Company without cause, or the CEO terminates his employment for “good reason” (each as defined in the employment agreement), the CEO would be entitled to receive severance in an amount equal to his then annual base salary and certain benefits, plus $100,000 (in lieu of bonus). In addition, pursuant to the employment agreement, the CEO would also be entitled to receive such severance in the event that the term of his employment agreement is not extended beyond December 31, 2017 and, within three months of such expiration date, his employment is terminated by the Company without “cause” or the CEO terminates his employment for any reason. Further, in the event that the CEO’s employment is terminated by the Company without cause, or the CEO terminates his employment for “good reason”, following a “change in control” (as defined in the employment agreement), the CEO would be entitled to receive severance in an amount equal to one and one-half times his then annual base salary and certain benefits, plus $300,000 (in lieu of bonus).	Litigations, Claims and Assessments
	On March 9, 2015, the Company agreed to amend the at-will employment agreement with its Vice President of Research and Development (“VP of R&D”). Pursuant to the employment agreement, as amended, in the event that the VP of R&D’s employment with the Company is terminated without cause, the VP of R&D would currently be entitled to receive a cash severance payment equal to one-half of his base annual salary (such one-half amount currently $125,000).	In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business.
		In November 2013, an action was commenced against the Company in the Circuit Court of Palm Beach County, Florida by an alleged former consultant. The action is associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009. Pursuant to the action, the plaintiff is seeking to recover an unspecified amount of damages but at least approximately $193,000 of cash (or alternatively $52,000 per year from September 2009) as well as the repayment of the alleged loan with interest, reimbursement for certain out-of-pocket fees and expenses, two weeks vacation pay per year, and the issuance of 80,000 shares of the Company’s common stock or warrants for the purchase of 80,000 shares of the Company’s common stock (or alternatively the market value of such securities). A trial of the action is scheduled to commence in June 2015. On March 13, 2015, the Company filed with the court a settlement offer in an amount which has been accrued.
		The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.
		Research Agreements
		Effective June 15, 2012, the Company entered into an assignment agreement (the “Assignment Agreement”) with the research foundation of a state university (the “Foundation”), whereby the Foundation assigned all of its right, title and interest in specified patents to the Company in exchange for a cash payment of $15,000. The Company also agreed to pay the Foundation a 5% royalty on Patent Revenue (as defined in the Assignment Agreement) over a 20 year period commencing on June 15, 2012. Through December 31, 2014, no royalties have been earned.
		Effective June 15, 2012, the Company entered into a research agreement (the “Research Agreement”) with the same state university (the “University”). The Research Agreement has a term of three years. Pursuant to the Research Agreement, the University agreed to perform certain research services to be used by the Company. Pursuant to the Research Agreement, the Company agreed to pay the University a fee of $500,000 for each twelve month period of the agreement, payable monthly. In addition, the Company agreed to pay to the University a 5% royalty, over a 20 year period commencing on June 15, 2012, on the net sales of all products and/or methods directly arising from inventions and improvements conceived or reduced to practice by the University in the course of performing research during the term of the Research Agreement. The Research Agreement can be cancelled without penalty upon (a) the second anniversary of the Research Agreement if eventual FDA approval does not appear likely or (b) other conditions specified in the Research Agreement. Through December 31, 2014, no royalties have been earned.
		On May 9, 2014, the Company entered into an amendment to the Research Agreement. Pursuant to the amendment, the parties agreed that (i) no fees are payable by the Company to the University pursuant to the Research Agreement for the first five monthly payments in 2014 ($208,335 of fees in total were cancelled, of which, $104,168 was accrued for as of March 31, 2014), (ii) effective with the payment due on June 15, 2014, the monthly fee payable by the Company to the University pursuant to the Research Agreement will be reduced from $41,667 to $20,000 and (iii) the scope of the work to be performed by the University pursuant to the Research Agreement was reduced. The Research Agreement, as amended, is scheduled to expire on June 14, 2015. Concurrent with the execution of the amendment, the Company paid $323,336 to the University, representing the balance due of all fees payable by the Company to date pursuant to the Research Agreement. As a result of the above, the Company recorded an immediate gain on settlement in the amount of $166,668.
		During the years ended December 31, 2014 and 2013, the Company recorded research and development expense of approximately $264,000 and $500,000, respectively in connection with the Research Agreement. As of December 31, 2014 and 2013, the Company had accrued approximately $43,000 and $353,000, respectively, in connection with the Research Agreement, which is included in accounts payable and accrued expenses and other current liabilities in the consolidated balance sheets.
		Consulting Agreements
		Marketing Consulting Services
		On June 27, 2014, a February 17, 2011 agreement for marketing consulting services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and provided for an expiration date of December 31, 2014 (the “New Marketing Consulting Term”). In consideration of services rendered during the New Marketing Consulting Term and the settlement of the Company’s obligation to pay $65,000 in cash to the consultant, the Company issued to a designee of the consultant 500,000 shares of common stock and issued to the consultant an immediately vested five-year warrant to purchase 250,000 shares of common stock at an exercise price of $1.00 per share. The common stock and warrant had grant date values of $110,000 and $37,500, respectively, which were recognized immediately. During the years ended December 31, 2014 and 2013, the Company recorded consulting expense of $82,500 and $120,000, respectively, related to the marketing consulting agreement.
		Consulting Services
		On February 20, 2014, the Company executed a two-year consulting agreement with the Physiatrist-In-Chief Emeritus for the Hospital for Special Surgery in New York City to become the Company’s Chief Medical Advisor for Spine Medicine pursuant to which he oversees the clinical aspects of the brtxDISC™ Program. The agreement may be terminated earlier or extended, as provided for in the agreement. Pursuant to the agreement, the consultant is entitled to receive $10,000 per month, escalating to $20,000 per month upon the FDA approval of the Company’s Investigational New Drug or Investigational Device Exemption application with respect to its brtxDISC™ Program. In addition, the Company granted the consultant a five-year option to purchase 300,000 shares of common stock at an exercise price of $0.65 per share, pursuant to the Plan. The option vests ratably over three years on the grant date anniversaries and the grant date value of $67,830 will be recognized proportionate to the vesting period. On October 8, 2014, the consulting agreement between the Company and its Chief Medical Advisor for Spine Medicine was amended such that the consultant will be entitled to receive $15,000 per month (and eliminated the possible increase to $20,000 per month). In connection with the amendment, the consultant was issued a five-year option to purchase 500,000 shares of the Company’s common stock at an exercise price of $0.32 per share. The option vests ratably over three years on the grant date anniversaries and the grant date value of $124,200 will be recognized proportionate to the vesting period.
		On March 12, 2014, as additional compensation for consulting services rendered, the Company granted to a consultant an immediately vested, five-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.53 per share. In addition, warrants to purchase an aggregate of 280,000 shares of common stock had their exercise prices reduced to $0.53 per share from $1.50 per share and such warrants, as well as a warrant to purchase 20,000 shares of common stock, had their term extended to March 12, 2019. The grant date value of the issued warrant of $23,270 along with the incremental value related to the modification of the outstanding warrants of $30,096 was recognized during the year ended December 31, 2014 as stock-based compensation expense, which is reflected as consulting expense in the consolidated statements of operations.
		On July 23, 2014, the Company entered into a one-year agreement with a consultant to market research and development arrangements and other business transactions to potential strategic partners and other alliance candidates. In exchange for services provided by the consultant during the term, the Company agreed to issue 30,000 shares of common stock of the Company for each complete month during the term. During the year ended December 31, 2014, the Company issued to the consultant an aggregate 150,000 shares of common stock and the aggregate grant date value of $33,000 was recognized immediately.
		On October 7, 2014, the Company entered into an agreement with a consultant for services regarding the search for a President for the Company’s Disc/Spine Division. The consultant was entitled to an initial retainer fee of $15,000, payable in shares of the Company’s common stock, and a second retainer fee of $10,000 to be paid in cash. A final fee will be invoiced upon a selected candidate’s acceptance of BRT’s offer and commencement of employment equal to 28% of the candidate’s first year base salary less the initial $25,000 retainer fee. Pursuant to the agreement, the Company issued 48,388 shares of common stock related to the initial retainer to the consultant and the $15,000 grant date value was reflected as consulting expense in the consolidated statements of operations. See Note 11 – Subsequent Events for additional details.
		Business Advisory Services
		On June 27, 2014, a February 17, 2011 agreement for business advisory services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and provided for an expiration date of December 31, 2014 (the “New Business Advisory Term”). In consideration of services rendered during the New Business Advisory Term, the Company agreed to pay a cash fee of $16,667 per month and the Company granted an immediately vested five-year warrant to purchase 250,000 shares of common stock at an exercise price of $1.00 per share. The warrant had a grant date value of $37,500 which was recognized immediately. On August 27, 2014, the Company and the consultant entered into an agreement pursuant to which the consultant waived the Company’s obligation to pay $75,000 of accrued cash compensation to the consultant, in exchange for 300,000 shares of the Company’s common stock. On December 19, 2014, the agreement was further amended such that the term of the agreement was extended an additional six months until June 30, 2015. During the additional six-month period, the Company agreed to pay a cash fee of $15,000 per month and the Company granted an immediately vested five-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.50 per share. The warrant had a grant date value of $17,000 which was recognized immediately. During the years ended December 31, 2014 and 2013, the Company recorded cash consulting fee expense of $150,000 and $120,000, respectively, related to the business advisory agreement.
		Scientific Advisory Services
		On March 27, 2013, the Company granted a ten-year option to a member of its Scientific Advisory Board to purchase 60,000 shares of common stock at an exercise price of $1.50 per share, pursuant to the Plan. The shares vest as follows: (i) 30,000 shares immediately and (ii) 30,000 shares on the first anniversary of the grant date. The grant date value of $45,900 was recognized half immediately and half proportionate to the vesting period.
		On June 10, 2013, the Company granted a five-year option to a member of its Scientific Advisory Board to purchase 5,000 shares of immediately-vested common stock at an exercise price of $1.00 per share, pursuant to the Plan. The grant date value of $2,056 was recognized immediately.
		On July 2, 2013, the Company granted a ten-year option to a member of its Scientific Advisory Board to purchase 100,000 shares of common stock at an exercise price of $1.00 per share, pursuant to the Plan. The shares vest as follows: (i) 50,000 shares immediately and (ii) 50,000 shares on the first anniversary of the grant date. The grant date value of $47,960 was recognized half immediately and half proportionate to the vesting period.
		On March 14, 2014, the Company executed an agreement, which will continue until terminated by either party, appointing a new Scientific Advisory Board member. Pursuant to the agreement, the Company immediately granted the new advisor a five-year option to purchase 25,000 shares of common stock at an exercise price of $0.50 per share, pursuant to the Plan. The option vests as follows: (i) 12,500 shares immediately and (ii) 12,500 shares on the first anniversary of the grant date. In addition, on each annual anniversary date of the agreement, the advisor is entitled to a new five-year option to purchase 5,000 shares of the Company’s common stock at an exercise price equal to the then fair market value of the common stock. The option grant date value of $5,860 will be recognized proportionate to the vesting period.
		On June 27, 2014, an August 16, 2012 agreement for scientific advisory services was further extended to August 16, 2016 such that the consultant will continue to serve as Chairman of the Company’s Scientific Advisory Board, will earn $10,000 per month and will be entitled to specified expense reimbursements. In addition, the Company granted a ten-year option to purchase 300,000 shares of common stock at an exercise price of $0.285 per share, pursuant to the Plan. The option vests as follows: (i) 150,000 shares on August 16, 2015 and (ii) 150,000 shares on August 16, 2016. The option grant date value of $81,000 will be recognized proportionate to the vesting period.
		Other
		On March 20, 2013, the Company granted an immediately vested, three-year warrant to purchase 10,000 shares of common stock at an exercise price of $1.50 per share to a consultant. The grant date value of $6,600 was recognized immediately.
		On March 22, 2013, the Company granted an immediately vested, five-year warrant to purchase 100,000 shares of common stock at an exercise price of $4.00 per share as consideration for legal services. The grant date value of $59,000 was recognized immediately.
		On December 23, 2013, the Company granted immediately vested, five-year warrants to purchase an aggregate of 100,000 shares of common stock at an exercise price of $2.00 per share to consultants. The aggregate grant date value of $16,770 was recognized immediately.
		On July 22, 2014, the Company granted a consultant an immediately vested five-year warrant to purchase 10,000 shares of common stock at an exercise price of $0.75 per share. The aggregate grant date value of $1,500 was recognized immediately.
		In addition to the issuances discussed elsewhere in this filing, during the years ended December 31, 2014 and 2013, an aggregate of 474,373 and 129,537 shares of immediately vested common stock valued at $159,837 and $77,555, respectively, were issued to consultants for various services rendered to the Company.
		Employment Agreements
		Chief Executive Officer
		Effective December 2013, the Company and its Chief Executive Officer (“CEO”) agreed that the CEO’s 2013 salary would be reduced from $600,000 to $360,000 and that his 2013 bonus of $300,000 and his 2013 vacation pay of $25,000 would be waived. As a result, the Company imputed the value of the services contributed and recorded salary expense of $565,000 for the year ended December 31, 2013 with a corresponding credit to stockholders’ deficiency.
		During the year ended December 31, 2014, the Company and its CEO approved amendments to the employment agreement between the Company and the CEO, dated October 4, 2010, as amended, providing for (a) a reduction of the CEO’s annual salary from $600,000 to $450,000, effective October 1, 2014, and (b) a reduction of the CEO’s annual salary from $450,000 to $400,000, effective January 1, 2015. During the years ended December 31, 2014 and 2013, the Company recorded $450,000 and $600,000, respectively, in operating expenses with regard to the CEO’s base salary.
		As of December 31, 2014 and 2013, the accrued and unpaid compensation (salary, bonus, tax liability, car allowance and vacation pay) for the CEO was $574,278 and $542,535, respectively, and was included in accrued expenses and other current liabilities in the consolidated balance sheets. See Note 11– Subsequent Events for additional details.
		Other
		In addition to the Company’s employment agreement with its CEO, as of December 31, 2014, two employees have “at-will” employment agreements with the Company that currently provide for aggregate cash severance payments of $175,000, payable over twelve months, upon involuntary termination. See Note 11– Subsequent Events for additional details.
		Board of Directors
		On June 27, 2014, a director of the Company resigned due to other business commitments. In consideration of director services performed to date, the Company agreed to pay an aggregate of $80,000 (of which, $50,000 was previously earned and accrued for), payable as follows: (i) $30,000 immediately and (ii) the $50,000 balance in six equal monthly installments commencing on July 31, 2014. In addition, all outstanding options held by the director which were not exercisable as of the date of resignation became exercisable on the earlier of (i) the date on which such options were scheduled to become exercisable or (ii) December 31, 2014, and all outstanding options shall remain exercisable until their respective expiration dates notwithstanding the director’s resignation. As a result of the modification of the options, the Company recorded incremental stock-based compensation expense of $96,250.
		On June 27, 2014, the Company elected two new directors. Concurrent with the election, the Company granted the new directors ten-year options to purchase an aggregate of 600,000 shares of common stock at an exercise price of $0.285 per share, pursuant to the Plan. The options vest as follows: (i) an aggregate of 200,000 shares on the date of grant; (ii) an aggregate of 200,000 shares on the first anniversary of the date of grant; and (iii) an aggregate of 200,000 shares on the second anniversary of the date of grant. The options have an aggregate grant date value of $144,000 which will be recognized proportionate to the vesting period.
		As of December 31, 2014 and 2013, $105,000 and $130,000 of director cash compensation, respectively, was outstanding and included in accrued expenses and other current liabilities in the consolidated balance sheets.
		Related Party Agreement
		Effective October 1, 2014, the Company entered into a three-month agreement with an affiliate of one of its directors for consulting services related to the Company’s brtxDISC™ Program and ThermoStem® Program. Pursuant to the agreement, the affiliate of the director was entitled to a cash fee of $10,000 per month and an amount of common stock having a fair market value of $5,000 as of the last day of each month during the term. On December 19, 2014, the agreement was amended such that the term of the agreement was extended until March 31, 2015. During the year ended December 31, 2014, the Company issued 36,786 shares of common stock pursuant to the agreement with a grant date fair value of $15,000.

Stockholders_Deficiency

Stockholders' Deficiency	3 Months Ended														12 Months Ended
	Mar. 31, 2015														Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 7 – Stockholders’ Deficiency														Note 10 – Stockholders’ Deficiency
	Authorized Capital														Authorized Capital
	On December 19, 2014, effective January 1, 2015, the Company’s shareholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware and in connection therewith (i) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000; and (ii) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of preferred stock authorized to be issued by the Company from 1,000,000 to 5,000,000.														As of December 31, 2014, the Company was authorized to issue 100,000,000 shares of common stock, $0.001 par value, and 1,000,000 shares of preferred stock, $0.01 par value. The holders of the Company’s common stock are entitled to one vote per share. Subject to the rights of holders of preferred stock, if any, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Subject to the rights of holders of preferred stock, if any, upon liquidation, dissolution or winding up of the Company, holders of common stock are entitled to share ratably in all assets of the Company that are legally available for distribution.
	Warrant and Option Valuation														On December 19, 2014, effective January 1, 2015, the Company’s shareholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware and in connection therewith (i) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000; and (ii) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of preferred stock authorized to be issued by the Company from 1,000,000 to 5,000,000.
	The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0% to 5% for options granted during the three months ended March 31, 2015 and 2014. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee and director option grants. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.														2010 Equity Participation Plan
	Common Stock and Warrant Offerings														On February 18, 2014 and October 23, 2014, the Board of Directors of the Company approved successive increases in the number of shares of common stock authorized to be issued pursuant to the Plan from 6,000,000 to 12,000,000 and then to 20,000,000. On December 19, 2014, the Company’s shareholders approved an increase in the number of shares of common stock authorized to be issued pursuant to the Plan to 20,000,000.
	During the three months ended March 31, 2015, the Company issued an aggregate of 2,703,333 shares of common stock at prices ranging from $0.25 to $0.30 per share to investors for aggregate gross proceeds of $801,000. In connection with the purchases, the Company issued warrants to purchase an aggregate of 850,833 shares of common stock at exercise prices ranging from $0.40 to $0.75 per share of common stock. The warrants have a term of five years. The warrants had an aggregate issuance date value of $138,383.														Common Stock and Warrant Offerings
	Stock Warrants														During the year ended December 31, 2013, the Company issued an aggregate of 840,589 shares of common stock at prices ranging from $0.85 to $1.50 per share to investors for aggregate gross proceeds of $905,000. In connection with the purchases, the Company issued five-year warrants to purchase an aggregate of 403,590 shares of common stock at exercise prices ranging from $1.50 to $4.00 per share of common stock. The warrants had an aggregate grant date value of $224,313.
	In applying the Black-Scholes option pricing model to warrants granted/issued, the Company used the following assumptions:														During the year ended December 31, 2014, the Company issued an aggregate of 8,671,983 shares of common stock at prices ranging from $0.25 to $0.45 per share to investors for aggregate gross proceeds of $2,605,000. In connection with the purchases, the Company issued warrants to purchase an aggregate of 2,330,693 shares of common stock at exercise prices ranging from $0.30 to $0.75 per share of common stock. The warrants have terms ranging from two to five years. The warrants had an aggregate grant date value of $389,608.
			For The Three Months Ended
			March 31,												See Note 7 – Notes Payable for details associated with common stock issued in conjunction with the extension and exchange of notes payable and related accrued interest.
			2015				2014
	Risk free interest rate			1.22% - 1.61	%			0.39% - 2.20	%						See Note 9 – Commitments and Contingencies – Consulting Agreements for details associated with common stock issued in conjunction with consulting agreements.
	Expected term (years)			5				1.96 - 5.00
	Expected volatility			122	%			121	%						Warrant and Option Valuation
	Expected dividends			0	%			0	%
															The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0% to 5% for options granted during the years ended December 31, 2014 and 2013. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.
	The weighted average estimated fair value of the warrants granted/issued during the three months ended March 31, 2015 and 2014 was approximately $0.16 and $0.22 per share, respectively.
															Warrant Exercise and Reload Program
	See Note 7 – Stockholders’ Deficiency – Common Stock and Warrant Offerings for details associated with the issuance of warrants in connection with common stock and warrant offerings.
															On November 27, 2013, the Company initiated a limited time program (the “Warrant Exercise and Reload Program”) which, at the election of any warrant holder, would permit them to immediately exercise their outstanding exercisable warrants at an exercise price of $0.30 per share. In connection with the exercise of the warrant, in addition to having received the number of shares pursuant to such exercise, each holder received a new warrant for the same number of shares purchased with an exercise price of $0.75 per share and an expiration date two years from the date of grant. The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $1.25 for five consecutive trading days. Under the Warrant Exercise and Reload Program, warrants to purchase an aggregate of 376,667 and 1,686,029 shares of common stock were exercised during the years ended December 31, 2014 and 2013, respectively, for aggregate gross proceeds of $113,000 and $505,809, respectively. The Company recognized a warrant modification charge of $50,035 and $214,912 during the years ended December 31, 2014 and 2013, respectively, which represents the incremental value of the modified warrant and new warrant combined, as compared to the original warrant value, all valued as of the respective modification dates.
	The Company recorded stock–based compensation expense of $0 and $53,726 during the three months ended March 31, 2015 and 2014, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the condensed consolidated statements of operations. As of March 31, 2015, there was no unrecognized stock-based compensation expense related to stock warrants.
															Stock Warrants
	A summary of the warrant activity during the three months ended March 31, 2015 is presented below:
															In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions:
									Weighted
						Weighted			Average								For The Year Ended
						Average			Remaining			Aggregate					December 31,
			Number of			Exercise			Life			Intrinsic					2014				2013
			Warrants			Price			In Years			Value			Risk free interest rate			0.39% - 2.20	%			0.34% - 1.68	%
	Outstanding, December 31, 2014			8,248,683		$	0.9								Expected term (years)			1.96 - 5.00				3.00 - 5.00
	Granted			850,833			0.68								Expected volatility			116% - 122	%			132% - 135	%
	Exercised			-			-								Expected dividends			0	%			0	%
	Forfeited			-			-
	Outstanding, March 31, 2015			9,099,516		$	0.88			3.1		$	-		The weighted average estimated fair value of the warrants granted during the years ended December 31, 2014 and 2013 was approximately $0.17 and $0.36 per share, respectively.
	Exercisable, March 31, 2015			8,399,516		$	0.83			3.2		$	-
															See Note 7 – Notes Payable for details associated with the issuance of warrants in connection with note issuances and the exchange of notes payable. See Note 9 – Commitments and Contingencies – Consulting Agreements for details associated with the issuance of warrants as compensation. See Note 10 – Stockholders’ Deficiency – Common Stock and Warrant Offerings for details associated with the issuance of warrants in connection with common stock and warrant offerings.
	The following table presents information related to stock warrants at March 31, 2015:
															The Company recorded stock–based compensation expense of $185,266 and $26,777 during the years ended December 31, 2014 and 2013, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the consolidated statements of operations. As of December 31, 2014, there was no unrecognized stock-based compensation expense related to stock warrants.
	Warrants Outstanding							Warrants Exercisable
								Weighted							A summary of the warrant activity during the years ended December 31, 2014 and 2013 is presented below:
					Outstanding			Average			Exercisable
	Exercise				Number of			Remaining Life			Number of													Weighted
	Price				Warrants			In Years			Warrants									Weighted				Average
																				Average				Remaining			Aggregate
	$	0.3				650,000			4.2			650,000					Number of			Exercise				Life			Intrinsic
		0.4				250,000			4.7			250,000					Warrants			Price				In Years			Value
		0.5				677,100			4.7			677,100			Outstanding, December 31, 2012			3,334,800		$	1.69
		0.53				380,000			3.1			380,000			Granted			3,147,119			1.56
		0.58				50,000			4.5			50,000			Exercised			-1,686,029			0.3	[1]
		0.75				4,669,222			2.9			4,669,222			Forfeited			-			-
		0.94				50,000			4.5			50,000			Outstanding, December 31, 2013			4,795,890		$	1.39
		1				550,000			4.2			550,000			Granted			3,849,460			0.7
		1.5				862,800			2.2			862,800			Exercised			-376,667			0.3	[1]
		1.75				20,000			2			20,000			Forfeited			-20,000			0.5
		2				123,530			3.6			123,530			Outstanding, December 31, 2014			8,248,683		$	0.9				3.2		$	-
		2.5				20,000			2.3			20,000
		3				36,864			3.1			36,864			Exercisable, December 31, 2014			7,548,683		$	0.84				3.3		$	-
		4				60,000			2.5			60,000
		Variable	[1]			700,000			-			-				[1]	During the year ended December 31, 2013, warrants to purchase an aggregate of 1,686,029 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program. During the year ended December 31, 2014, warrants to purchase an aggregate of 376,667 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program.
						9,099,516			3.2			8,399,516
															The following table presents information related to stock warrants at December 31, 2014:
		[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur as of March 31, 2015.
															Warrants Outstanding						Warrants Exercisable
Stock Options																				Weighted
																				Average			Exercisable
In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:														Exercise			Number of			Remaining Life			Number of
														Price			Warrants			In Years			Warrants
	For the Three Months Ended
	March 31,													$	0.3			650,000			4.4			650,000
	2015					2014									0.4			200,000			4.9			200,000
Risk free interest rate			1.33% - 1.64	%			1.5	%							0.5			502,100			4.8			502,100
Expected term (years)			5.00 - 6.00				5.00 - 5.50								0.53			380,000			3.4			380,000
Expected volatility			122	%			121	%							0.58			50,000			4.8			50,000
Expected dividends			0	%			0	%							0.75			4,043,389			2.8			4,043,389
															0.94			50,000			4.8			50,000
The weighted average estimated fair value of the stock options granted during the three months ended March 31, 2015 and 2014 was approximately $0.40 and $0.23 per share, respectively.															1			550,000			4.4			550,000
															1.5			862,800			2.5			862,800
															1.75			20,000			2.3			20,000
See Note 6 – Commitments and Contingencies – Employment Agreements for details associated with the grant of stock options in connection with employment agreements.															2			123,530			3.9			123,530
															2.5			20,000			2.6			20,000
On January 23, 2015, the Company granted five-year options to consultants to purchase an aggregate of 100,000 shares of common stock at an exercise price of $0.47 per share, pursuant to the Plan. The shares vest as follows: (i) 75,000 shares vest ratably over three months from the date of grant, (ii) 12,500 shares vest immediately and (iii) 12,500 shares vest on the anniversary of the date of grant. The aggregate grant date value of $39,200 will be recognized proportionate to the vesting period.															3			36,864			3.3			36,864
															4			60,000			2.8			60,000
The following table presents information related to stock option expense:															Variable	[1]		700,000			-			-
												Weighted						8,248,683			3.3			7,548,683
												Average
		For the Three Months Ended						Unrecognized at				Amortization			[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2014.
		March 31,						March 31,				Period
		2015			2014			2015				(Years)		Stock Options
Consulting		$	96,803		$	100,613		$	585,273				2.3	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:
Research and development			128,432			121,390			755,231	[1]			2.4
General and administrative			69,285			83,699			862,726				2.4			For the Year Ended
																December 31,
		$	294,520		$	305,702		$	2,203,230				2.4			2014				2013
														Risk free interest rate			1.50% - 2.54	%			1.13% - 2.66	%
	[1]	Includes $331,341 of expense that is subject to non-employee mark-to-market adjustments.												Expected term (years)			5.00 - 10.00				5.00 - 10.00
														Expected volatility			116% - 122	%			132% - 135	%
A summary of the option activity during the three months ended March 31, 2015 is presented below:														Expected dividends			0	%			0	%
								Weighted
					Weighted			Average						The weighted average estimated fair value of the stock options granted during the years ended December 31, 2014 and 2013 was approximately $0.27 and $0.26 per share, respectively.
					Average			Remaining			Aggregate
		Number of			Exercise			Life			Intrinsic			See Note 9 – Commitments and Contingencies for details associated with certain grants of options as compensation to employees, directors and consultants.
		Options			Price			In Years			Value
														On October 4, 2013, the Company granted ten-year options to employees, directors, and an advisor to purchase an aggregate of 980,000 shares of common stock at an exercise price of $0.60 per share, pursuant to the Plan. The shares vest as follows: (i) 490,000 shares immediately and (ii) 490,000 shares on the first anniversary of the grant date. The grant date value of $199,921 was recognized proportionate to the vesting period.
Outstanding, December 31, 2014			15,584,000		$	0.61
Granted			600,000			0.46								Between February 18, 2014 and March 12, 2014, the Company granted ten-year options to employees and directors to purchase an aggregate of 2,415,000 shares of common stock at exercise prices ranging from $0.53 to $0.65 per share, pursuant to the Plan. The shares vest as follows: (i) 831,669 shares immediately and (ii) 1,589,331 shares ratably over two years on the grant date anniversaries. The aggregate grant date value of $566,483 will be recognized proportionate to the vesting period.
Exercised			-			-
Forfeited			-			-								On June 16, 2014, the Company granted a five-year option to a consultant to purchase 60,000 shares of common stock at an exercise price of $0.39 per share, pursuant to the Plan. The shares vest ratably over three months on the grant date anniversaries. The grant date value of $18,600 was recognized proportionate to the vesting period.
Outstanding, March 31, 2015			16,184,000		$	0.6			8.3		$	587,850
														On September 24, 2014, the Company granted a five-year option to a consultant to purchase 75,000 shares of common stock at an exercise price of $0.33 per share, pursuant to the Plan. The shares vest ratably over three months on the grant date anniversaries. The grant date value of $20,100 was recognized proportionate to the vesting period.
Exercisable, March 31, 2015			7,196,502		$	0.88			7.5		$	28,850
														On October 23, 2014, the Company granted ten-year options to employees and directors to purchase an aggregate of 5,950,000 shares of common stock at an exercise price of $0.33 per share, pursuant to the Plan. The shares vest ratably over three years on the grant date anniversaries. The grant date value of $1,710,400 will be recognized proportionate to the vesting period.
The following table presents information related to stock options at March 31, 2015:
														On October 27, 2014, the Company granted a ten-year option to an advisor to purchase 250,000 shares of common stock at an exercise price of $0.34 per share, pursuant to the Plan. The shares vest ratably over three years on the grant date anniversaries. The grant date value of $78,500 will be recognized proportionate to the vesting period.
Options Outstanding						Options Exercisable
						Weighted								On November 17, 2014, the Company granted a ten-year option to an employee to purchase 100,000 shares of common stock at an exercise price of $0.33 per share, pursuant to the Plan. The shares vest ratably over three years on the grant date anniversaries. The grant date value of $31,600 will be recognized proportionate to the vesting period.
			Outstanding			Average			Exercisable
Exercise			Number of			Remaining Life			Number of
Price			Options			In Years			Options					The following table presents information related to stock option expense:
$	0.285			900,000			9.2			200,000																Weighted
	0.32			500,000			-			-																Average
	0.33			6,125,000			4.5			75,000						For the Year Ended						Unrecognized at				Amortization
	0.34			250,000			-			-						December 31,						December 31,				Period
	0.39			60,000			4.2			60,000						2014			2013			2014				(Years)
	0.46			500,000			-			-
	0.47			100,000			4.8			87,500				Consulting		$	365,825		$	160,894		$	654,956				2.6
	0.5			345,000			4.6			345,000				Research and development			328,740			251,758			712,551	[1]			2.5
	0.53			40,000			8.9			40,000				General and administrative			179,628			235,163			961,378				2.6
	0.6			980,000			8.5			980,000
	0.65			2,675,000			8.6			1,850,002						$	874,193		$	647,815		$	2,328,885				2.6
	1			131,000			7.7			131,000
	1.05			2,270,000			6.9			2,270,000					[1]	Includes $448,189 of expense that is subject to non-employee mark-to-market adjustments.
	1.1			5,000			2.2			5,000
	1.2			10,000			1.2			10,000				As of December 31, 2014, there was $2,328,885 of unrecognized compensation expense which will be amortized over the weighted average remaining vesting period of 2.6 years.
	1.25			43,000			1.6			43,000
	1.4			350,000			4.3			200,000				A summary of the option activity during the years ended December 31, 2014 and 2013 is presented below:
	1.5			900,000			7.7			900,000
				16,184,000			7.5			7,196,502											Weighted
																			Weighted		Average
Compensatory Common Stock Issuances																			Average		Remaining				Aggregate
																Number of			Exercise		Life				Intrinsic
During the three months ended March 31, 2015, the Company issued an aggregate of 312,795 shares of common stock valued at $85,128 to consultants pursuant to consulting agreements.																Options			Price		In Years				Value
The following table presents information related to compensatory common stock expense and does not include 18,847 shares valued at $8,481 which were issued in satisfaction of accrued professional services:														Outstanding, December 31, 2012			4,018,000		$	1.12
														Granted			1,145,000			0.68
		For the Three Months Ended						Unrecognized at						Exercised			-			-
		March 31,						March 31,						Forfeited			-120,000			0.5
		2015			2014			2015						Outstanding, December 31, 2013			5,043,000		$	1.03
														Granted			10,575,000			0.41
Consulting		$	67,800		$	10,000		$	-					Exercised			-			-
Research and development			8,847			4,071			-					Forfeited			-34,000			1.31
														Outstanding, December 31, 2014			15,584,000		$	0.61			8.5		$	979,600
		$	76,647		$	14,071		$	-
														Exercisable, December 31, 2014			6,371,502		$	0.91			7.6		$	45,600
A summary of compensatory common stock issuances activity during the three months ended March 31, 2015 is presented below:
														The following table presents information related to stock options at December 31, 2014:
					Weighted
					Average			Total						Options Outstanding						Options Exercisable
		Number of			Issuance Date			Issuance Date												Weighted
		Shares			Fair Value			Fair Value									Outstanding			Average			Exercisable
														Exercise			Number of			Remaining Life			Number of
Non-vested, December 31, 2014			-		$	-		$	-					Price			Options			In Years			Options
Granted			312,795			0.27			85,128
Vested			-312,795			-0.27			-85,128					$	0.285			900,000			9.5			200,000
Forfeited			-			-			-						0.32			500,000			-			-
Non-vested, March 31, 2015			-		$	-		$	-						0.33			6,125,000			4.7			75,000
															0.34			250,000			-			-
															0.39			60,000			4.5			60,000
															0.5			345,000			4.9			332,500
															0.53			40,000			9.2			40,000
															0.6			980,000			8.8			980,000
															0.65			2,675,000			9.1			1,125,002
															1			131,000			8			131,000
															1.05			2,270,000			7.1			2,270,000
															1.1			5,000			2.4			5,000
															1.2			10,000			1.4			10,000
															1.25			43,000			1.9			43,000
															1.4			350,000			4.5			200,000
															1.5			900,000			7.9			900,000
																		15,584,000			7.6			6,371,502
														Compensatory Common Stock Issuances
														See Note 9 – Commitments and Contingencies for details associated with certain issuances of common stock as compensation to employees, directors and consultants.
														On October 4, 2013, the Company issued 50,000 shares of immediately vested common stock to its legal counsel. The $12,500 grant date fair value was recognized immediately.
														Between June 27, 2014 and December 31, 2014, the Company issued 150,000 shares of immediately vested common stock to its legal counsel. The $33,000 grant date fair value was recognized immediately.
														The following table presents information related to compensatory common stock issuances expense during the years ended December 31, 2014 and 2013:
																For the Year Ended						Unrecognized at
																December 31,						December 31,
																2014			2013			2014
														Consulting		$	276,500		$	111,351		$	-
														Research and development			24,337			26,704			-
																$	300,837		$	138,055		$	-
														A summary of compensatory common stock issuances activity during the years ended December 31, 2014 and 2013 is presented below:
																			Weighted
																			Average			Total
																Number of			Issuance Date			Issuance Date
																Shares			Fair Value			Fair Value
														Non-vested, December 31, 2012			-		$	-		$	-
														Granted			239,537			0.58			138,055
														Vested			-239,537			0.58			-138,055
														Forfeited			-			-			-
														Non-vested, December 31, 2013			-		$	-		$	-
														Granted			1,943,747			0.26			511,886
														Vested			-1,943,747			-0.26			-511,886
														Forfeited			-			-			-
														Non-vested, December 31, 2014			-		$	-		$	-

Subsequent_Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Note 8 - Subsequent Events	Note 11 - Subsequent Events
	Common Stock and Warrant Offerings	Research and Development Agreements; Bermuda Lender
	Subsequent to March 31, 2015, the Company issued an aggregate of 700,000 shares of common stock at prices ranging from $0.25 to $0.30 per share to investors for gross proceeds of $200,000. In connection with the purchases, the Company issued five-year warrants to purchase an aggregate of 175,000 shares of common stock at an exercise price of $0.75 per share of common stock.	Subsequent to December 31, 2014, the Company received the third and fourth payments of four quarterly payments in the aggregate amount of $177,234 pursuant to the research and development agreement with a U.S. pharmaceutical company discussed in Note 3 – Summary of Significant Accounting Policies – Revenue Recognition – Research and Development Agreements. This payment triggered the mandatory principal prepayment of $177,237 of the note payable that was issued to the Bermuda Lender on May 8, 2014. As of the filing date of this report, $266,297 of mandatory prepayments to the Bermuda Lender related to the research agreement were unpaid.
	Stock-Based Compensation	Subsequent to December 31, 2014, the Company received payment in the amount of $50,000 pursuant to the research and development agreement with a Japanese pharmaceutical company discussed in Note 3 – Summary of Significant Accounting Policies – Revenue Recognition – Research and Development Agreements. As of the filing date of this report, a $50,000 mandatory prepayment to the Bermuda Lender related to the research and development agreement was unpaid.
	Subsequent to March 31, 2015, the Company issued an aggregate of 144,616 shares of common stock and five-year warrants to purchase an aggregate of 600,000 shares of common stock at exercise prices ranging from $0.38 to $0.60 per share to satisfy certain consulting and other obligations.	Short Term Advances
	Board of Directors	Subsequent to December 31, 2014, the Company received an aggregate of $60,055 in non-interest bearing advances from an officer and made aggregate repayments of $60,055.
	On April 6, 2015, the Company elected a new director to replace a director who had previously resigned. Concurrent with the election, the Company granted a ten-year option to purchase 300,000 shares of common stock at an exercise price of $0.40 per share, pursuant to the Plan. The shares vest ratably over three years on the grant date anniversaries.	Notes Payable
	Short Term Advances	Subsequent to December 31, 2014, the Company issued a convertible note with a principal amount of $30,000 which bears interest at a rate of 12% annum payable upon maturity. The convertible note, is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at the greater of (a) 55% of the fair value of the Company’s stock or (b) $0.10 per share.
	Subsequent to March 31, 2015, the Company received an aggregate of $84,015 in non-interest bearing advances from an officer and made aggregate repayments of $135,030.	Subsequent to December 31, 2014, the Company elected to convert a convertible note with a principal balance of $50,000 and accrued interest of $5,984 into 222,245 shares of common stock at a conversion price of $0.25 per share.
	Notes Payable	Notes payable, non-current portion represents notes payable that were either exchanged for equity or whose maturities were extended past December 31, 2015 after the balance sheet date but before the consolidated financial statements were issued. Accrued interest, non-current portion represents the accrued interest that, after the balance sheet date but before the consolidated financial statements were issued, was either exchanged for equity or converted into the principal amount of a note payable classified as non-current.
	On May 8, 2015, the Company issued a six-month convertible note with a principal amount of $100,000 which bears interest at a rate of 10% per annum payable upon maturity. The convertible note is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to at the greater of (a) 65% of the fair value of the Company’s stock or (b) $0.15 per share. In connection with the financing, a five-year warrant to purchase 126,923 shares of common stock at an exercise price of $0.50 per share was issued to the lender.	Employment Agreements
	On May 11, 2015, Cayman and the Bermuda Lender agreed to extend the maturity date of a note with a principal balance of $410,938 from May 7, 2015 to June 30, 2015 (the “New Maturity Date”). The Bermuda Lender waived any and all defaults under the note, including with respect to the failure by the Company to pay to the Bermuda Lender pursuant to the note the aggregate amount of $316,297 (the “Unpaid Amount”) received by the Company from its research and development agreements (see Note 3 – Summary of Significant Accounting Policies – Revenue Recognition – Research and Development Agreements). The extension agreement provided for the payment of the Unpaid Amount on the New Maturity Date together with all other amounts then payable pursuant to the note.	On February 9, 2015, the Company hired a President for its Disc/Spine Division. As compensation the Company granted to the President of its Disc/Spine Division a ten-year option to purchase 500,000 shares of common stock at an exercise price of $0.46 per share, pursuant to the Plan. The shares vest annually over three years on the grant date anniversaries.
	On May 11, 2015, 2015, pursuant to the provisions of a convertible note with a principal balance of $75,000, the Company elected to convert the initial $25,000 of principal, together with accrued interest of $1,205, into 118,043 shares of common stock at a conversion price of $0.22 per share. On May 21, 2015, pursuant to the provisions of the convertible note, the Company elected to convert the second $25,000 of principal, together with accrued interest of $1,301, into 101,943 shares of common stock at a conversion price of $0.26 per share.	On March 9, 2015, the Company and the CEO agreed to extend the term of his employment agreement to December 31, 2017. Pursuant to the employment agreement, the CEO is entitled to receive a salary of $400,000 per annum. The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Company’s Compensation Committee, are satisfied. Pursuant to the employment agreement, in the event that the CEO’s employment is terminated by the Company without “cause”, or the CEO terminates his employment for “good reason” (each as defined in the employment agreement), the CEO would be entitled to receive severance in an amount equal to one time his then annual base salary and certain benefits, plus $100,000 (in lieu of bonus). In addition, pursuant to the employment agreement, the CEO would be entitled to receive such severance in the event that the term of his employment agreement is not extended beyond December 31, 2017 and, within three months of such expiration date, his employment is terminated by the Company without “cause” or the CEO terminates his employment for any reason. Further, in the event that the CEO’s employment is terminated by the Company without “cause”, or the CEO terminates his employment for “good reason”, following a “change in control” (as defined in the employment agreement), the CEO would be entitled to receive severance in an amount equal to one and one-half times his then annual base salary and certain benefits, plus $300,000 (in lieu of bonus).
	On May 14, 2015, the Company and a lender agreed to exchange a note payable with a principal balance of $282,873, along with accrued and unpaid interest of $25,296, for 1,027,231 shares of common stock and an immediately vested, five-year warrant to purchase 256,808 shares of common stock at an exercise price of $0.75 per share. In connection with the exchange, the Company extended the expiration date of a previously outstanding warrant to purchase 140,000 shares of common stock from December 31, 2015 to December 31, 2017.	On March 9, 2015, the Company agreed to amend the at will employment agreement with its Vice President of Research and Development (“VP of R&D”). Pursuant to the employment agreement, as amended, in the event that the VP of R&D’s employment with the Company is terminated without cause, the VP of R&D would currently be entitled to receive a cash severance payment of $125,000.
	On May 14, 2015, the Company issued a convertible note in the principal amount of $100,000 which bears interest at a rate of 10% per annum payable on maturity. The convertible note is payable as follows: (i) $25,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the “First Maturity Date”), (ii) $25,000 of principal and the respective accrued interest on such principal is payable two weeks following the First Maturity Date (the “Second Maturity Date”), (iii) $25,000 of principal and the respective accrued interest on such principal is payable four weeks following the First Maturity Date (the “Third Maturity Date”) and (iv) $25,000 of principal and the respective accrued interest on such principal is payable six weeks following the First Maturity Date (the “Fourth Maturity Date”). Each $25,000 of principal and the respective accrued interest on such principal is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at a conversion price equal to the greater of (a) 62% of the fair value of the Company’s stock or (b) $0.15 per share. In the event that the Company elects to effect a conversion, then, during the five day period following the conversion, the holder shall have the right to convert the then outstanding principal amount of the convertible note, together with accrued and unpaid interest thereon, into shares of the Company’s common stock at a conversion price equal to the conversion price in the Company-effected conversion.	Common Stock and Warrant Offerings
	On May 20, 2015, the Company issued a six-month convertible note with a principal amount of $50,000 which bears interest at a rate of 10% per annum payable upon maturity. The convertible note is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) 65% of the fair value of the Company’s stock; or (b) $0.15 per share. In connection with the financing, a five-year warrant to purchase 58,929 shares of common stock at an exercise price of $0.50 per share was issued to the lender.	Subsequent to December 31, 2014, the Company issued an aggregate of 2,703,333 shares of common stock at prices ranging from $0.25 to $0.30 per share to investors for aggregate gross proceeds of $801,000. In connection with the purchases, the Company issued warrants to purchase an aggregate of 850,833 shares of common stock at exercise prices ranging from $0.40 to $0.75 per share of common stock. The warrants have a term of five years. In connection with the common stock and warrant offerings, a previously outstanding warrant to purchase 80,000 shares of common stock at an exercise price of $0.75 per share had its expiration date extended from December 31, 2015 to December 31, 2016.
	On May 27, 2015, the Company and the Bermuda Lender agreed to exchange five notes with an aggregate principal amount of $4,410,938 and aggregate accrued interest of $69,436 for 14,934,578 shares of common stock and an immediately vested five-year warrant to purchase 3,733,645 shares of common stock at an exercise price of $0.75 per share. In connection with the exchange, the Company extended the expiration date of a previously outstanding warrant to purchase 800,000 shares of common stock from December 31, 2015 to December 31, 2017.	Stock-Based Compensation
	On May 27, 2015, the Company and a lender agreed to exchange a note payable with a principal balance of $50,000 for 166,667 shares of common stock and an immediately vested, five-year warrant to purchase 41,667 shares of common stock at an exercise price of $0.75 per share. In connection with the exchange, the Company extended the expiration date of a previously outstanding warrant to purchase 35,000 shares of common stock from December 31, 2015 to December 31, 2017.	Subsequent to December 31, 2014, the Company issued an aggregate of 270,295 shares of common stock valued at $73,528 to consultants pursuant to consulting agreements.
	On May 27, 2015, the Company and a lender agreed to exchange two notes payable with an aggregate principal balance of $260,000 for 866,667 shares of common stock and an immediately vested, five-year warrant to purchase 216,667 shares of common stock at an exercise price of $0.75 per share. In connection with the exchange, the Company extended the expiration date of previously outstanding warrants to purchase an aggregate of 130,000 shares of common stock from December 31, 2015 to December 31, 2017.	On January 23, 2015, the Company granted a five-year option to consultants to purchase an aggregate 100,000 shares of common stock at an exercise price of $0.47 per share, pursuant to the Plan. The shares vest as follows: (i) 75,000 shares vest ratably over three months on the grant date anniversaries, (ii) 12,500 shares vest immediately and (iii) 12,500 shares vest on the grant date anniversary.
	On May 29, 2015, the Company extended the expiration date of previously outstanding warrants to purchase an aggregate of 100,000 shares of common stock from December 31, 2015 to December 31, 2017.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation					Principles of Consolidation
	The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation.					The consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates					Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s equity securities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.					The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s equity securities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations and Credit Risk	Concentrations and Credit Risk					Concentrations and Credit Risk
	As of March 31, 2015, 76% of the face value of the Company’s outstanding notes payable were sourced from a single entity (the “Bermuda Lender”). As of the date of filing, the maturity date associated with these notes was June 30, 2015. See Note 5 – Notes Payable and Note 8 – Subsequent Events – Note Payable for additional discussion of the Bermuda Lender.					As of December 31, 2014, 75% of the face value of the Company’s outstanding notes payable were sourced from a single entity (the “Bermuda Lender”) and the maturity dates associated with these notes range from May 7, 2015 to June 30, 2015. See Note 7 – Notes Payable for additional discussion of the Bermuda Lender.
	Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three months ended March 31, 2015. See Revenue Recognition – Research and Development Agreements below.					Two pharmaceutical clients comprised substantially all of the Company’s revenue during the year ended December 31, 2014. See Revenue Recognition – Research and Development Agreements below.
Cash						Cash
						The Company maintains cash in bank accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to be negligible.
Inventories						Inventories
						The Company maintains finished goods inventories, consisting of Stem Pearls skincare products, which are available for sale. Inventories are stated at the lower of cost or market. Cost is determined by the first-in, first-out method.
						The Company periodically reviews for slow-moving, excess or obsolete inventories. Products that are determined to be obsolete, if any, are written down to net realizable value. During the year ended December 31, 2014, the Company recorded an inventory write-down of $15,407.
Property and Equipment						Property and Equipment
						Property and equipment are stated at cost, net of accumulated depreciation which is recorded commencing at the in-service date using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 3 to 5 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred.
Intangible Assets						Intangible Assets
						Intangible assets are comprised of trademarks and licenses with original estimated useful lives of 10 and 17.7 years (20 year life of underlying patents which the Company is licensing, less 2.3 years elapsed since the application date of the respective patents), respectively. Once placed into service, the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis.
Impairment of Long-lived Assets						Impairment of Long-lived Assets
						The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company has not identified any such impairment losses.
Revenue Recognition	Revenue Recognition					Revenue Recognition
	Research and Development Agreements					Research and Development Agreements
	The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables.					The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables.
	During the three months ended March 31, 2015, in connection with a March 19, 2014 research and development agreement with a Japanese pharmaceutical company, the Company received $50,000 upon achievement of a specified deliverable (milestone method). Through March 31, 2015, $200,000 had been received under the agreement and recognized as revenue. On February 11, 2015, the term of the agreement was extended by three months to June 19, 2015.					On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $150,000 received at commencement (straight-line method);  (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). As of December 31, 2014, the initial $150,000 payment had been received and $34,281 remained in deferred revenues on the consolidated balance sheet. On February 11, 2015, the term of the agreement was extended by three months to June 19, 2015.
	During the three months ended March 31, 2015, in connection with a March 24, 2014 research and development agreement with a U.S. pharmaceutical company, the Company received the third and fourth of four quarterly payments in the aggregate amount of $177,234. Through March 31, 2015, $605,359 had been received and $210,882 was recorded as deferred revenues on the condensed consolidated balance sheet.					On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments (all of which are being recognized pursuant to the straight-line method), subject to acceleration upon achieving a specified deliverable. As of December 31, 2014, the initial $250,000 payment and the first two quarterly payments of $89,063 related to (2) above had been received and $130,068 was recorded as deferred revenues on the consolidated balance sheet.
	During the three months ended March 31, 2015, the Company recognized revenue related to research and development agreements of $180,702. The Company did not recognize any revenue related to research and development agreements during the three months ended March 31, 2014.					During the year ended December 31, 2014, the Company recognized revenue related to research and development agreements of $413,777. The Company did not recognize any revenue related to research and development agreements during the year ended December 31, 2013.
	Other					Other
	The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.					The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.
	For the three months ended March 31, 2015 and 2014, the Company recognized revenue related to sales of Stem Pearls® skincare products of $200 and $375, respectively. In connection with its January 27, 2012 sublicense agreement with a stem cell treatment company, for the three months ended March 31, 2015 and 2014, the Company recognized royalty revenue of $4,000 and $0, respectively.					For the years ended December 31, 2014 and  2013, the Company recognized revenue related to sales of Stem Pearls® skincare products of $2,219 and $1,680, respectively.
Income Taxes						Income Taxes
						The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.
						The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
						Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of December 31, 2014 and 2013. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.
						The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.
Net Loss Per Common Share	Net Loss Per Common Share					Net Loss Per Common Share
	Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes.					Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes.
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:					The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		March 31,
		2015		2014			December 31,
	Options		16,184,000		7,783,000		2014		2013
	Warrants		9,099,516		5,325,751	Options		15,584,000		5,043,000
	Convertible instruments		678,806		1,519,015	Warrants		8,248,683		4,795,890
	Total potentially dilutive shares		25,962,322		14,627,766	Convertible notes		653,885		1,063,380
						Total potentially dilutive shares		24,486,568		10,902,270
Stock-Based Compensation	Stock-Based Compensation					Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTCQB. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.					The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTC Bulletin Board. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
Advertising						Advertising
						Advertising costs are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred advertising costs of $15,280 and $25,748, respectively. Advertising expense is reflected in marketing and promotion expenses in the consolidated statements of operations.
Research and Development						Research and Development
						Research and development expenses are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred research and development expenses of $1,430,614 and $1,594,054, respectively.
Reclassifications						Reclassifications
						Certain prior period amounts have been reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the previously reported net loss.
Fair Value of Financial Instruments						Fair Value of Financial Instruments
						The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
						ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
						Level 1 — quoted prices in active markets for identical assets or liabilities
						Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
						Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)
						The carrying amounts of cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. The carrying amounts of our short term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, taken together with other features such as concurrent issuance of warrants, are comparable to rates of returns for instruments of similar credit risk.
Convertible Instruments						Convertible Instruments
						GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP.
						When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
Subsequent Events	Subsequent Events					Subsequent Events
	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.					The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed in Note 11.
Recently Issued Accounting Pronouncements						Recently Issued Accounting Pronouncements
						In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition (“ASC 605”) and most industry-specific guidance throughout ASC 605. The standard requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.
						In June 2014, the FASB issued ASU No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation,” (“ASU 2014-10”). ASU 2014-10 removes the definition of a development stage entity from the Master Glossary of the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company adopted ASU 2014-10 during the year ended December 31, 2014 which resulted in the removal of previously required development stage disclosures. The Company’s planned principal operations are to develop technology using cell and tissue therapy protocols, primarily involving adult stem cells, allowing patients to undergo cellular-based treatments. The Company has established a new laboratory facility and is seeking to increase its capabilities for the further development of possible cellular-based treatment protocols, stem cell-related intellectual property and research applications. The Company’s activities are subject to significant risks and uncertainties, which are detailed in Note 2 – Going Concern and Management’s Plans.
						In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of ASU 2014-12 will have a material impact on its consolidated financial statements.
						In August 2014, the FASB issued ASU No. 2014-15,”Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company elected to adopt ASU 2014-15. Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 2 – Going Concern and Management’s Plans.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:					The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		March 31,
		2015		2014			December 31,
	Options		16,184,000		7,783,000		2014		2013
	Warrants		9,099,516		5,325,751	Options		15,584,000		5,043,000
	Convertible instruments		678,806		1,519,015	Warrants		8,248,683		4,795,890
	Total potentially dilutive shares		25,962,322		14,627,766	Convertible notes		653,885		1,063,380
						Total potentially dilutive shares		24,486,568		10,902,270

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment include the following:
		December 31,
		2014		2013
	Office equipment	$	8,466	$	7,670
	Medical equipment		359,248		129,461
	Furniture and fixtures		113,874		19,322
	Computer software and equipment		66,458		20,169
	Leasehold Improvements		103,582		-
			651,628		176,622
	Less: accumulated depreciation		-157,772		-141,054
	Property and equipment, net	$	493,856	$	35,568

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Intangible Assets [Abstract]
Schedule Of Intangible Assets By Major Class	Intangible assets consist of the following:
		Patents and				Accumulated
		Trademarks		Licenses		Amortization		Total
	Balance as of January 1, 2013	$	3,676	$	1,226,500	$	-52,819	$	1,177,357
	Amortization expense		-		-		-69,812		-69,812
	Balance as of December 31, 2013	$	3,676	$	1,226,500	$	-122,631	$	1,107,545
	Amortization expense		-		-		-69,813		-69,813
	Balance as of December 31, 2014	$	3,676	$	1,226,500	$	-192,444	$	1,037,732
	Weighted average remaining amortization period at December 31, 2014 in years		6		14.9
Schedule Of FiniteLived Intangible Assets Amortization Expense	Amortization of intangible assets consists of the following:
		Patents and				Accumulated
		Trademarks		Licenses		Amortization
	Balance as of January 1, 2013	$	736	$	52,083	$	52,819
	Amortization expense		368		69,444		69,812
	Balance as of December 31, 2013	$	1,104	$	121,527	$	122,631
	Amortization expense		368		69,445		69,813
	Balance as of December 31, 2014	$	1,472	$	190,972	$	192,444

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following:					Accrued expenses and other current liabilities are comprised of the following:
		March 31,		December 31,			December 31,
		2015		2014			2014		2013
		(unaudited)
						Credit card payable	$	4,739	$	6,000
	Credit card payable	$	3,971	$	4,739	Accrued payroll and payroll taxes		679,277		672,535
	Accrued payroll and payroll taxes		777,757		679,277	Accrued purchases of property and equipment		174,801		-
	Accrued purchases of property and equipment		74,587		174,801	Accrued research and development expenses		292,395		229,276
	Accrued research and development expenses		316,175		292,395	Accrued general and administrative expenses		315,294		266,541
	Accrued general and administrative expenses		679,069		315,294	Deferred rent		-		2,310
	Deferred rent		33,000		-	Total	$	1,466,506	$	1,176,662
	Total	$	1,884,559	$	1,466,506

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended													12 Months Ended
	Mar. 31, 2015													Dec. 31, 2014
Notes Payable [Abstract]
Notes Payable	A summary of the notes payable activity during the three months ended March 31, 2015 is presented below:													A summary of the notes payable activity during the years ended December 31, 2014 and 2013 is presented below:
			Bermuda		Convertible			Other		Debt
			Lender		Notes			Notes		Discount		Total				Bermuda		Convertible			Other			Debt
																Lender		Notes			Notes			Discount			Total
	Outstanding, December 31, 2014		$	4,410,937	$	175,000		$	1,265,559	$	-113,257	$	5,738,239
	Issuance			-		30,000			-		-		30,000	Outstanding, December 31, 2012		$	3,550,000	$	-		$	1,082,185		$	-76,719		$	4,555,466
	Conversion to equity			-		-50,000			-		-		-50,000	Issuances			450,000		281,000	[1]		733,000			-			1,464,000
	Recognition of debt discount			-		-			-		-16,590		-16,590	Conversion of accrued interest			-		-			68,100			-			68,100
	Amortization of debt discount			-		-			-		69,515		69,515	Exchanges for equity			-		-			-404,285			-			-404,285
	Outstanding, March 31, 2015		$	4,410,937	$	155,000	[1]	$	1,265,559	$	-60,332	$	5,771,164	Repayments			-		-			-5,500			-			-5,500
														Recognition of debt discount			-		-			-			-574,369	[1]		-574,369
		[1]	As of March 31, 2015, convertible notes with an aggregate principal balance of $155,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.											Amortization of debt discount			-		-			-			405,531			405,531
														Accretion of interest expense			-		-			-			5,066	[1]		5,066
														Outstanding, December 31, 2013		$	4,000,000	$	281,000		$	1,473,500		$	-240,491		$	5,514,009
														Issuances			500,000		300,000	[1]		-			-			800,000
														Exchanges for equity			-		-71,000			-203,000			-			-274,000
														Conversions to equity			-		-342,500			-			-			-342,500
														Repayments			-89,063		-			-113,000			-			-202,063
														Recognition of debt discount			-		-			-			-347,170	[1]		-347,170
														Amortization of debt discount			-		-			-			464,470			464,470
														Recharacterization of accrued interest as principal			-		-			108,059	[3]		-			108,059
														Accretion of interest expense			-		15,000	[2]		-			9,934	[1]		24,934
														Settlement of accreted interest			-		-7,500	[2]		-			-			-7,500
														Outstanding, December 31, 2014		$	4,410,937	$	175,000	[4]	$	1,265,559		$	-113,257		$	5,738,239
															[1]	During the years ended December 31, 2014 and 2013, notes with an aggregate principal amounts of $30,000 and $60,000, respectively, bear no interest and were issued for cash consideration of $25,000 and $50,000, respectively. The differences between the principal amounts of the notes and the cash received of $5,000 and $10,000, respectively, were recorded as debt discount and amortized to interest expense over the term of the notes.
															[2]	During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to June 10, 2014, the aggregate principal balance of the notes was increased from $90,000 to $105,000. The aggregate $15,000 of principal increases was accreted as interest expense. During the year ended December 31, 2014, $7,500 of the principal increases was settled by the conversion of a convertible note with a maturity date of January 8, 2014 and original principal balance of $30,000 into shares of the Company's common stock.
															[3]	During the year ended December 31, 2014, in connection with the extension of certain notes payable with maturity dates ranging from of August 8, 2013 to March 1, 2014, an aggregate $108,059 of accrued interest was added to the aggregate principal balance of the notes, increasing the aggregate principal balance from $752,500 to $860,559.
															[4]	As of December 31, 2014, convertible notes with an aggregate principal balance of $175,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Tax effects of temporary differences that give rise to deferred tax assets	United States and foreign components of loss before income taxes were as follows:
		For The Years Ended
		December 31,
		2014			2013
	United States	$	-5,223,749		$	-5,328,958
	Foreign		-363,863			-422,236
	Loss before income taxes	$	-5,587,612		$	-5,751,194
	The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:
		For The Years Ended
		December 31,
		2014			2013
	Deferred Tax Assets:
	Net operating loss carryforward	$	4,820,500		$	5,327,000
	Stock-based compensation		1,272,600			907,100
	Accruals		240,700			139,800
	Research & development tax credits		95,500			-
	Other		2,100			2,700
	Gross deferred tax assets		6,431,400			6,376,600
	Deferred Tax Liabilities:
	Fixed assets		-93,200			-
	Intangible assets		-8,100			-3,000
	Gross deferred tax liabilities		-101,300			-3,000
	Net deferred tax assets		6,330,100			6,373,600
	Valuation allowance		-6,330,100			-6,373,600
	Deferred tax asset, net of valuation allowance	$	-		$	-
	Changes in valuation allowance	$	-43,500		$	1,631,300
Income tax provision (benefit)	The income tax provision (benefit) consists of the following:
		For The Years Ended
		December 31,
		2014			2013
	Federal:
	Current	$	-		$	-
	Deferred		38,921			-1,459,584
	State and local:
	Current		-			-
	Deferred		4,579			-171,716
			43,500			-1,631,300
	Change in valuation allowance		-43,500			1,631,300
	Income tax provision (benefit)	$	-		$	-
Reconciliation of effective tax rate	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		For The Years Ended
		December 31,
		2014				2013
	Tax benefit at federal statutory rate		-34	%			-34	%
	State income taxes, net of federal benefit		-4	%			-4	%
	Permanent differences		0.8	%			5.8	%
	Research & development tax credits		-1.8	%			0	%
	Impact of Section 382 limit		41.2	%			0	%
	True-ups and other		-1.4	%			1.6	%
	Change in valuation allowance		-0.8	%			30.6	%
	Effective income tax rate		0	%			0	%

Stockholders_Deficiency_Tables

Stockholders' Deficiency (Tables)	3 Months Ended														12 Months Ended
	Mar. 31, 2015														Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Black-Scholes Option Pricing Model to Warrants Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to warrants granted/issued, the Company used the following assumptions:														In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions:
			For The Three Months Ended
			March 31,														For The Year Ended
			2015				2014										December 31,
	Risk free interest rate			1.22% - 1.61	%			0.39% - 2.20	%								2014				2013
	Expected term (years)			5				1.96 - 5.00							Risk free interest rate			0.39% - 2.20	%			0.34% - 1.68	%
	Expected volatility			122	%			121	%						Expected term (years)			1.96 - 5.00				3.00 - 5.00
	Expected dividends			0	%			0	%						Expected volatility			116% - 122	%			132% - 135	%
															Expected dividends			0	%			0	%
Summary of Warrant Activity	A summary of the warrant activity during the three months ended March 31, 2015 is presented below:														A summary of the warrant activity during the years ended December 31, 2014 and 2013 is presented below:
									Weighted															Weighted
						Weighted			Average											Weighted				Average
						Average			Remaining			Aggregate								Average				Remaining			Aggregate
			Number of			Exercise			Life			Intrinsic					Number of			Exercise				Life			Intrinsic
			Warrants			Price			In Years			Value					Warrants			Price				In Years			Value
	Outstanding, December 31, 2014			8,248,683		$	0.9								Outstanding, December 31, 2012			3,334,800		$	1.69
	Granted			850,833			0.68								Granted			3,147,119			1.56
	Exercised			-			-								Exercised			-1,686,029			0.3	[1]
	Forfeited			-			-								Forfeited			-			-
	Outstanding, March 31, 2015			9,099,516		$	0.88			3.1		$	-		Outstanding, December 31, 2013			4,795,890		$	1.39
															Granted			3,849,460			0.7
	Exercisable, March 31, 2015			8,399,516		$	0.83			3.2		$	-		Exercised			-376,667			0.3	[1]
															Forfeited			-20,000			0.5
															Outstanding, December 31, 2014			8,248,683		$	0.9				3.2		$	-
															Exercisable, December 31, 2014			7,548,683		$	0.84				3.3		$	-
																[1]	During the year ended December 31, 2013, warrants to purchase an aggregate of 1,686,029 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program. During the year ended December 31, 2014, warrants to purchase an aggregate of 376,667 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program.
Information Related to Stock Warrants	The following table presents information related to stock warrants at March 31, 2015:														The following table presents information related to stock warrants at December 31, 2014:
	Warrants Outstanding							Warrants Exercisable							Warrants Outstanding						Warrants Exercisable
								Weighted													Weighted
					Outstanding			Average			Exercisable										Average			Exercisable
	Exercise				Number of			Remaining Life			Number of				Exercise			Number of			Remaining Life			Number of
	Price				Warrants			In Years			Warrants				Price			Warrants			In Years			Warrants
	$	0.3				650,000			4.2			650,000			$	0.3			650,000			4.4			650,000
		0.4				250,000			4.7			250,000				0.4			200,000			4.9			200,000
		0.5				677,100			4.7			677,100				0.5			502,100			4.8			502,100
		0.53				380,000			3.1			380,000				0.53			380,000			3.4			380,000
		0.58				50,000			4.5			50,000				0.58			50,000			4.8			50,000
		0.75				4,669,222			2.9			4,669,222				0.75			4,043,389			2.8			4,043,389
		0.94				50,000			4.5			50,000				0.94			50,000			4.8			50,000
		1				550,000			4.2			550,000				1			550,000			4.4			550,000
		1.5				862,800			2.2			862,800				1.5			862,800			2.5			862,800
		1.75				20,000			2			20,000				1.75			20,000			2.3			20,000
		2				123,530			3.6			123,530				2			123,530			3.9			123,530
		2.5				20,000			2.3			20,000				2.5			20,000			2.6			20,000
		3				36,864			3.1			36,864				3			36,864			3.3			36,864
		4				60,000			2.5			60,000				4			60,000			2.8			60,000
		Variable	[1]			700,000			-			-				Variable	[1]		700,000			-			-
						9,099,516			3.2			8,399,516							8,248,683			3.3			7,548,683
		[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur as of March 31, 2015.													[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2014.
Black-Scholes Option Pricing Model to Stock Options Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:														In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:
		For the Three Months Ended															For the Year Ended
		March 31,															December 31,
		2015					2014										2014				2013
	Risk free interest rate			1.33% - 1.64	%			1.5	%						Risk free interest rate			1.50% - 2.54	%			1.13% - 2.66	%
	Expected term (years)			5.00 - 6.00				5.00 - 5.50							Expected term (years)			5.00 - 10.00				5.00 - 10.00
	Expected volatility			122	%			121	%						Expected volatility			116% - 122	%			132% - 135	%
	Expected dividends			0	%			0	%						Expected dividends			0	%			0	%
Stock option expense	The following table presents information related to stock option expense:														The following table presents information related to stock option expense:
													Weighted
													Average														Weighted
			For the Three Months Ended						Unrecognized at				Amortization														Average
			March 31,						March 31,				Period				For the Year Ended						Unrecognized at				Amortization
			2015			2014			2015				(Years)				December 31,						December 31,				Period
																	2014			2013			2014				(Years)
	Consulting		$	96,803		$	100,613		$	585,273				2.3
	Research and development			128,432			121,390			755,231	[1]			2.4	Consulting		$	365,825		$	160,894		$	654,956				2.6
	General and administrative			69,285			83,699			862,726				2.4	Research and development			328,740			251,758			712,551	[1]			2.5
															General and administrative			179,628			235,163			961,378				2.6
			$	294,520		$	305,702		$	2,203,230				2.4
																	$	874,193		$	647,815		$	2,328,885				2.6
		[1]	Includes $331,341 of expense that is subject to non-employee mark-to-market adjustments.
																[1]	Includes $448,189 of expense that is subject to non-employee mark-to-market adjustments.
Summary of Option Activity	A summary of the option activity during the three months ended March 31, 2015 is presented below:														A summary of the option activity during the years ended December 31, 2014 and 2013 is presented below:
									Weighted
						Weighted			Average													Weighted
						Average			Remaining			Aggregate								Weighted		Average
			Number of			Exercise			Life			Intrinsic								Average		Remaining
			Options			Price			In Years			Value					Number of			Exercise		Life				Intrinsic
																	Options			Price		In Years				Value
	Outstanding, December 31, 2014			15,584,000		$	0.61
	Granted			600,000			0.46								Outstanding, December 31, 2012			4,018,000		$	1.12
	Exercised			-			-								Granted			1,145,000			0.68
	Forfeited			-			-								Exercised			-			-
	Outstanding, March 31, 2015			16,184,000		$	0.6			8.3		$	587,850		Forfeited			-120,000			0.5
															Outstanding, December 31, 2013			5,043,000		$	1.03
	Exercisable, March 31, 2015			7,196,502		$	0.88			7.5		$	28,850		Granted			10,575,000			0.41
															Exercised			-			-
															Forfeited			-34,000			1.31
															Outstanding, December 31, 2014			15,584,000		$	0.61			8.5		$	979,600
															Exercisable, December 31, 2014			6,038,169		$	0.93			7.6		$	45,600
Information Related to Stock Options	The following table presents information related to stock options at March 31, 2015:														The following table presents information related to stock options at December 31, 2014:
	Options Outstanding						Options Exercisable								Options Outstanding						Options Exercisable
							Weighted														Weighted
				Outstanding			Average			Exercisable								Outstanding			Average			Exercisable
	Exercise			Number of			Remaining Life			Number of					Exercise			Number of			Remaining Life			Number of
	Price			Options			In Years			Options					Price			Options			In Years			Options
	$	0.285			900,000			9.2			200,000				$	0.285			900,000			9.5			200,000
		0.32			500,000			-			-					0.32			500,000			-			-
		0.33			6,125,000			4.5			75,000					0.33			6,125,000			4.7			75,000
		0.34			250,000			-			-					0.34			250,000			-			-
		0.39			60,000			4.2			60,000					0.39			60,000			4.5			60,000
		0.46			500,000			-			-					0.5			345,000			4.9			332,500
		0.47			100,000			4.8			87,500					0.53			40,000			9.2			40,000
		0.5			345,000			4.6			345,000					0.6			980,000			8.8			980,000
		0.53			40,000			8.9			40,000					0.65			2,675,000			9.1			1,125,002
		0.6			980,000			8.5			980,000					1			131,000			8			131,000
		0.65			2,675,000			8.6			1,850,002					1.05			2,270,000			7.1			2,270,000
		1			131,000			7.7			131,000					1.1			5,000			2.4			5,000
		1.05			2,270,000			6.9			2,270,000					1.2			10,000			1.4			10,000
		1.1			5,000			2.2			5,000					1.25			43,000			1.9			43,000
		1.2			10,000			1.2			10,000					1.4			350,000			4.5			200,000
		1.25			43,000			1.6			43,000					1.5			900,000			7.9			900,000
		1.4			350,000			4.3			200,000								15,584,000			7.6			6,371,502
		1.5			900,000			7.7			900,000
					16,184,000			7.5			7,196,502
Common Stock Award Expense	The following table presents information related to compensatory common stock expense and does not include 18,847 shares valued at $8,481 which were issued in satisfaction of accrued professional services:														The following table presents information related to compensatory common stock issuances expense during the years ended December 31, 2014 and 2013:
			For the Three Months Ended						Unrecognized at
			March 31,						March 31,								For the Year Ended						Unrecognized at
			2015			2014			2015								December 31,						December 31,
																	2014			2013			2014
	Consulting		$	67,800		$	10,000		$	-
	Research and development			8,847			4,071			-					Consulting		$	276,500		$	111,351		$	-
															Research and development			24,337			26,704			-
			$	76,647		$	14,071		$	-
																	$	300,837		$	138,055		$	-
Summary of Common Stock Award Activity	A summary of compensatory common stock issuances activity during the three months ended March 31, 2015 is presented below:														A summary of compensatory common stock issuances activity during the years ended December 31, 2014 and 2013 is presented below:
						Weighted														Weighted
						Average			Total											Average			Total
			Number of			Issuance Date			Issuance Date								Number of			Issuance Date			Issuance Date
			Shares			Fair Value			Fair Value								Shares			Fair Value			Fair Value
	Non-vested, December 31, 2014			-		$	-		$	-					Non-vested, December 31, 2012			-		$	-		$	-
	Granted			312,795			0.27			85,128					Granted			239,537			0.58			138,055
	Vested			-312,795			-0.27			-85,128					Vested			-239,537			0.58			-138,055
	Forfeited			-			-			-					Forfeited			-			-			-
	Non-vested, March 31, 2015			-		$	-		$	-					Non-vested, December 31, 2013			-		$	-		$	-
															Granted			1,943,747			0.26			511,886
															Vested			-1,943,747			-0.26			-511,886
															Forfeited			-			-			-
															Non-vested, December 31, 2014			-		$	-		$	-

Business_Organization_Nature_o1

Business Organization, Nature of Operations and Basis of Presentation - Additional Information (Detail)	0 Months Ended
	Apr. 15, 2013	Mar. 31, 2015	Jan. 01, 2015	Dec. 31, 2014	Dec. 19, 2014	Dec. 31, 2013
Business Organization and Nature Of Operations [Line Items]
Reverse stock split ratio	the Company implemented a 1-for-50 reverse split
Stockholders equity note, changes in capital structure, retroactive impact	1,500,000,000 to 100,000,000
Changes in capital structure retroactive impact shares	1,500,000,000
Common stock, authorized	100,000,000	200,000,000	200,000,000	200,000,000	20,000,000	200,000,000

Going_Concern_and_Managements_1

Going Concern and Management's Plans - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Working capital deficiency	$8,741,867		$8,410,686
Stockholders deficiency	-7,395,292		-6,888,393	-6,685,069	-5,141,693
Net loss	-1,760,121	-1,669,676	-5,587,612	-5,751,194
Note principal and accrued interest converted to equity			-274,000	-404,285
Subsequent Event
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount raised through debt financing	100,000		30,000
Amount raised through equity financing	200,000		801,000
Notes payable aggregate principal past due			5,000
Other Research and Development Expense			227,234
Subsequent Event | Notes Payable, Accrued Interest Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	26,501		5,984
Subsequent Event | Notes Payable, Principal Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	$307,873		$50,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended		12 Months Ended		1 Months Ended		3 Months Ended
	Jul. 15, 2014	Apr. 06, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 19, 2014	Mar. 24, 2014	Jun. 30, 2014
Summary Of Significant Accounting Policies [Line Items]
Debt instrument outstanding face amount percentage			76.00%		75.00%
Finite-Lived Intangible Asset, Useful Life		17 years 8 months 12 days
Advertising Expense					$15,280	$25,748
Research and Development Expense			406,856	493,741	1,430,614	1,594,054
Finite Lived Intangible Asset Useful Life From Application Date					2 years 3 months 18 days
Deferred Revenue, Current			210,882		164,349	0
Revenues			184,902	375	415,996	1,680
Cash Proceeds From Research Agreements	89,063
Inventory Write-down					15,407	0
Research and Development Agreements One Year
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Payment Terms			the Company received $50,000 upon achievement of a specified deliverable (milestone method). Through March 31, 2015, $200,000 had been received under the agreement and recognized as revenue.				Payment terms are (1) $150,000 received at commencement (straight-line method); (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). As of December 31, 2014, the initial $150,000 payment had been received and $34,281 remained in deferred revenues on the consolidated balance sheet.
Deferred Revenue, Current					150,000
Research and Development Agreements Two Year
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Payment Terms			payments in the aggregate amount of $177,234. Through March 31, 2015, $605,359 had been received and $210,882 was recorded as deferred revenues on the condensed consolidated balance sheet.					Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments (all three of which are being recognized pursuant to the straight-line method), subject to acceleration upon achieving a specified deliverable.
Deferred Revenue, Current			210,882		250,000			130,068
Cash Proceeds From Research Agreements				89,063					89,063
Research and development agreements
Summary Of Significant Accounting Policies [Line Items]
Revenues			180,702		413,777
Minimum
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life					3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life					5 years
Trademarks
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life					10 years
Stem Pearls Skincare Products
Summary Of Significant Accounting Policies [Line Items]
Revenue, Net, Total			200	375	2,219	1,680
Royalty Revenue			$4,000	$0
Licenses
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life					17 years 8 months 12 days
Patents
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life					20 years
Finite Lived Intangible Asset Useful Life From Application Date					2 years 3 months 18 days

Calculation_of_Weighted_Averag

Calculation of Weighted Average Dilutive Common Shares (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	25,962,322	14,627,766	24,486,568	10,902,270
Options
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	16,184,000	7,783,000	15,584,000	5,043,000
Warrants
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	9,099,516	5,325,751	8,248,683	4,795,890
Convertible instruments
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	678,806	1,519,015	653,885	1,063,380

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation	$26,872	$34,999

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Office equipment		$8,466	$7,670
Medical equipment		359,248	129,461
Furniture and fixtures		113,874	19,322
Computer software and equipment		66,458	20,169
Leasehold Improvements		103,582	0
Property, Plant and Equipment, Gross		651,628	176,622
Less: accumulated depreciation		-157,772	-141,054
Property and equipment, net	$537,155	$493,856	$35,568

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended	0 Months Ended	1 Months Ended
	Apr. 06, 2012	Dec. 31, 2014	Mar. 05, 2015	Jan. 27, 2012	Oct. 07, 2014	Feb. 20, 2014
Finite-Lived Intangible Assets [Line Items]
Grant date value		$124,200			$15,000	$67,830
Payment capitalized as intangible asset	1,000,000
Estimated useful life	17 years 8 months 12 days
Useful life lapsed since patent application		2 years 3 months 18 days
Amortization		70,000
Subsequent Event
Finite-Lived Intangible Assets [Line Items]
Warrant Issued To Purchase Common Stock		80,000
Exercise price of warrant		$0.75
Milestones payment			75,000
Patents
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	20 years
First Tranche
Finite-Lived Intangible Assets [Line Items]
Warrant Issued To Purchase Common Stock	300,000
Exercise price of warrant	$1.50
Grant date value	226,500
Payment capitalized as intangible asset	226,500
Second Tranche
Finite-Lived Intangible Assets [Line Items]
Warrant Issued To Purchase Common Stock	350,000
Exercise price of warrant	$1.50
Maximum | Subsequent Event
Finite-Lived Intangible Assets [Line Items]
Milestones payment			475,000
Minimum | Subsequent Event
Finite-Lived Intangible Assets [Line Items]
Milestones payment			225,000
License Agreement Terms
Finite-Lived Intangible Assets [Line Items]
Percentage of legal fees agreed to be reimbursed				25.00%
Net License fee paid	1,000,000
Licenses Revenue	10,000
Warrant Issued To Purchase Common Stock	1,000,000
License Agreement Terms | Maximum
Finite-Lived Intangible Assets [Line Items]
Legal fees agreed to be reimbursed				100,000
License Agreement Terms | Maximum | Monthly Payment
Finite-Lived Intangible Assets [Line Items]
Legal fees agreed to be reimbursed				4,500

Intangible_Assets_Detail

Intangible Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	$1,107,545	$1,177,357	$1,094,913
Amortization expense	-69,813	-69,812
Ending Balance	1,037,732	1,107,545	1,094,913
Patents and Trademarks
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	3,676	3,676
Amortization expense	0	0
Ending Balance	3,676	3,676
Weighted Average Amortization Period	6 years
Licensing Agreements
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	1,226,500	1,226,500
Amortization expense	0	0
Ending Balance	1,226,500	1,226,500
Weighted Average Amortization Period	14 years 10 months 24 days
Accumulated Amortization
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	-122,631	-52,819
Amortization expense	-69,813	-69,812
Ending Balance	($192,444)	($122,631)

Amortization_of_Intangible_Ass

Amortization of Intangible Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Patents and Trademarks
Accumulated Amortization [Line Items]
Beginning Balance	$1,104	$736
Amortization expense	368	368
Ending Balance	1,472	1,104
Licensing Agreements
Accumulated Amortization [Line Items]
Beginning Balance	121,527	52,083
Amortization expense	69,445	69,444
Ending Balance	190,972	121,527
Accumulated Amortization
Accumulated Amortization [Line Items]
Beginning Balance	122,631	52,819
Amortization expense	69,813	69,812
Ending Balance	$192,444	$122,631

Recovered_Sheet1

Accrued Expenses And Other Current Liabilities - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer	$125,070	$0	$58,054	$144,285
Repayment of advances from officer	60,055	24,990	83,044	119,295
Liability to officer	$65,015			$24,990

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities [Line Items]
Credit card payable	$3,971	$4,739	$6,000
Accrued payroll and payroll taxes	777,757	679,277	672,535
Accrued purchases of property and equipment	74,587	174,801	0
Accrued research and development expenses	316,175	292,395	229,276
Accrued general and administrative expenses	679,069	315,294	266,541
Deferred rent	33,000	0	2,310
Total	$1,884,559	$1,466,506	$1,176,662

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended		12 Months Ended		1 Months Ended	3 Months Ended	4 Months Ended	1 Months Ended
	Aug. 13, 2014	Jul. 15, 2014	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 02, 2014	2-May-14	Dec. 18, 2013	Mar. 26, 2013	8-May-14
Debt Instrument [Line Items]
Aggregate principal amount			$83,333			$83,333
Warrants aggregate grant date fair value			389,608			389,608	224,313
Debt instrument, face amount	4,000,000		7,500			7,500
Warrants to purchase common stock			2,330,693			2,330,693	403,590
Loss on extinguishment of note and payables, net				0	49,094	49,094	7,200
Accrued loan interest			108,059			108,059
Stock issued (in shares)	550,000
Common stock aggregate grant date fair value			74,029			74,029	3,704
Stock issued, amount				801,000
Warrant Issued During Period Relative Fair Value							112,239
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			190,000			190,000	402,500
Debt Instrument Periodic Payment Interest						15,000
Debt Instrument, Periodic Payment, Principal						175,000
Proceeds from Notes Payable				30,000	140,000	795,000	1,454,000
Debt Instrument, Convertible, Beneficial Conversion Feature				10,690	0	92,370	0
Debt Instrument, Interest Rate During Period						15.00%
Payments for royalties						100,000
Debt Conversion, Original Debt, Amount						30,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.75			$0.75
Debt Instrument, Maturity Date Range, Start	31-Jul-14					31-Dec-14
Debt Instrument, Maturity Date Range, End	31-Dec-14					30-Jun-15
Amortization Of Debt Discount (Premium)	121,000		99,000	69,515	98,505	464,470	405,531
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Principal Amount						71,000
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Interest Amount						4,260
Stock Issued During Period, Shares, Issued in Exchange of Notes Payable						246,764
Warrants Issued During Period, Number of Warrants1			100,000			100,000
Payments under Research and Development Agreements			113,000			113,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures						11,219
Cash Proceeds From Research Agreements		89,063
Warrants
Debt Instrument [Line Items]
Warrants aggregate grant date fair value			29,800			29,800
Notes Payable
Debt Instrument [Line Items]
Debt Instrument Annual Principal Payment			225,000			225,000
Debt Instrument, Increase, Accrued Interest						13,565
Conversion of Stock, Shares Issued						1,202,744
Notes Payable | Cayman
Debt Instrument [Line Items]
Debt instrument, face amount											3,550,000
First Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal								41,667
Second Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal								41,667
Third Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal								41,666
Minimum
Debt Instrument [Line Items]
Warrants exercise price			$0.30			$0.30	$1.50
Debt Instrument, Periodic Payment, Principal						752,500
Debt Instrument, Increase, Accrued Interest						90,000
Percentage of royalty payments						0.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.50			$0.50	$0.94
Minimum | Notes Payable
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price			$0.14			$0.14
Maximum
Debt Instrument [Line Items]
Warrants exercise price			$0.75			$0.75	$4
Debt Instrument, Periodic Payment, Principal						860,559
Debt Instrument, Increase, Accrued Interest						105,000
Percentage of royalty payments						4.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.75			$0.75	$2.50
Maximum | Notes Payable
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price			$0.28			$0.28
In exchange of notes payable
Debt Instrument [Line Items]
Warrants aggregate grant date fair value			268,997			268,997
Warrants exercise price			$0.75			$0.75	$1.50
Loss on extinguishment of note and payables, net						50,325	7,200
Stock issued (in shares)							5,000
Common stock aggregate grant date fair value							417,681
Amortization Of Debt Discount (Premium)				0		0	0
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Principal Amount						203,000	404,285
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Interest Amount						15,672	6,196
Stock Issued During Period, Shares, Issued in Exchange of Notes Payable						854,689	818,495
Warrants Issued During Period, Number of Warrants1			100,000			100,000	45,000
Convertible Notes
Debt Instrument [Line Items]
Aggregate principal amount				155,000					175,000	281,000
Rate of interest				12.00%				10.00%	12.00%	12.00%
Debt instrument, face amount				50,000
Loss on extinguishment of note and payables, net						1,231
Debt instrument conversion period description										The conversion price of the convertible notes is equal to the greater of (a) 55-65% (depending on the specific note) of the fair value of the Company’s common stock or (b) $0.05 per share. As of December 31, 2013, the convertible notes were not convertible. The beneficial conversion features will be accounted for, if necessary, at the commitment date.
Debt instrument, new proceeds									170,000	271,000
Debt Instrument Annual Principal Payment			30,000			30,000	60,000		30,000	60,000
Debt Instrument issued for consideration						25,000	50,000		25,000	50,000
Debt Instrument Periodic Payment Interest						5,000	10,000		5,000	10,000
Debt Instrument, Periodic Payment, Principal									145,000	221,000
Debt Instrument, Frequency of Periodic Payment									The convertible notes were initially payable 3-12 months from the date of issuance	Convertible Notes were initially payable 2-6 months from the date of issuance.
Proceeds from Notes Payable								125,000	175,000	281,000
Debt Instrument, Convertible, Beneficial Conversion Feature				10,690					145,000	171,000
Debt Instrument Convertible Number of stock to holders										110,000
Debt Instrument, Increase, Accrued Interest				5,984		3,646
Debt instrument, interest rate, effective percentage										100.00%
Amortization Of Debt Discount (Premium)				0		0	0
Conversion of Stock, Shares Issued						582,033
Debt Instrument, Convertible, Conversion Price				$0.10
Debt Instrument Issue Description									(a) 55%-60% (depending on the particular note) of the fair value of the Company’s stock or (b) $0.05 per share. The remaining $30,000 is convertible into shares of the Company’s common stock at the election of the holder any time after September 10, 2014 at the lesser of (a) $0.50 per share or (b) 65% of the fair value of the Company’s common stock, but with a floor of $0.05 per share.
Proceeds from Convertible Debt				30,000
Debt Instrument Percentage For Fair Value				55.00%
Sale of Stock, Number of Shares Issued in Transaction				222,245
Sale of Stock, Price Per Share				$0.25
Convertible Notes | Minimum
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price			$0.19			$0.19
Convertible Notes | Maximum
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price			$0.22			$0.22
Waiver
Debt Instrument [Line Items]
Aggregate principal amount											450,000
Accrued loan interest											213,000
Bermuda Lender
Debt Instrument [Line Items]
Aggregate principal amount				83,333								500,000
Scheduled maturity date of the note											31-Jul-14
Warrants aggregate grant date fair value											457,826
Warrants to purchase common stock											400,000
Warrants exercise price											$2.50
Stock issued (in shares)											600,000
Stock issued, amount											480,000
Fair value Of warrants											250,000
Stock issued during period shares in connection with accrued and unpaid interest											266,250
Debt instrument, interest rate, effective percentage											11.00%	15.00%
Bermuda Lender | Notes Payable | Cayman
Debt Instrument [Line Items]
Aggregate principal amount											450,000
Debt instrument, face amount											$4,000,000

Notes_Payable_Detail

Notes Payable (Detail) (USD $)	0 Months Ended	1 Months Ended		3 Months Ended			12 Months Ended
	Aug. 13, 2014	Dec. 31, 2014		Mar. 31, 2015		Mar. 31, 2014	Dec. 31, 2014		Dec. 31, 2013
Debt Instrument [Line Items]
Balance				$5,738,239		$5,514,009	$5,514,009		$4,555,466
Issuances				30,000			800,000		1,464,000
Conversion of accrued interest									68,100
Exchanges for equity							-274,000		-404,285
Conversions to equity				-50,000			-342,500
Repayments				0		-25,000	-202,063		-5,500
Recognition of debt discount				-16,590			-347,170		-574,369
Amortization of debt discount	121,000	99,000		69,515		98,505	464,470		405,531
Recharacterization of accrued interest as principal							108,059
Accretion of interest expense							24,934		5,066
Settlement of accreted interest							-7,500
Balance		5,738,239		5,771,164			5,738,239		5,514,009
Debt Discount
Debt Instrument [Line Items]
Balance				-113,257		-240,491	-240,491		-76,719
Issuances				0			0		0
Conversion of accrued interest									0
Exchanges for equity							0		0
Conversions to equity				0			0
Repayments							0		0
Recognition of debt discount				-16,590			-347,170	[1]	-574,369	[1]
Amortization of debt discount				69,515			464,470		405,531
Recharacterization of accrued interest as principal							0
Accretion of interest expense							9,934	[1]	5,066	[1]
Settlement of accreted interest							0
Balance		-113,257		-60,332			-113,257		-240,491
Bermuda Lender
Debt Instrument [Line Items]
Balance				4,410,937		4,000,000	4,000,000		3,550,000
Issuances				0			500,000		450,000
Conversion of accrued interest									0
Exchanges for equity							0		0
Conversions to equity				0			0
Repayments							-89,063		0
Recognition of debt discount				0			0		0
Amortization of debt discount				0			0		0
Recharacterization of accrued interest as principal							0
Accretion of interest expense							0		0
Settlement of accreted interest							0
Balance		4,410,937		4,410,937			4,410,937		4,000,000
Convertible Notes Payable
Debt Instrument [Line Items]
Balance				175,000	[2]	281,000	281,000		0
Issuances				30,000			300,000	[1]	281,000	[1]
Conversion of accrued interest									0
Exchanges for equity							-71,000		0
Conversions to equity				-50,000			-342,500
Repayments							0		0
Recognition of debt discount				0			0		0
Amortization of debt discount				0			0		0
Recharacterization of accrued interest as principal							0
Accretion of interest expense							15,000	[3]	0
Settlement of accreted interest							-7,500	[3]
Balance		175,000	[2]	155,000	[4]		175,000	[2]	281,000
Notes Payable, Other Payables
Debt Instrument [Line Items]
Balance				1,265,559		1,473,500	1,473,500		1,082,185
Issuances				0			0		733,000
Conversion of accrued interest									68,100
Exchanges for equity							-203,000		-404,285
Conversions to equity				0			0
Repayments							-113,000		-5,500
Recognition of debt discount				0			0		0
Amortization of debt discount				0			0		0
Recharacterization of accrued interest as principal							108,059
Accretion of interest expense							0	[5]	0
Settlement of accreted interest							0
Balance		$1,265,559		$1,265,559			$1,265,559		$1,473,500
[1]	During the years ended December 31, 2014 and 2013, notes with an aggregate principal amounts of $30,000 and $60,000, respectively, bear no interest and were issued for cash consideration of $25,000 and $50,000, respectively. The differences between the principal amounts of the notes and the cash received of $5,000 and $10,000, respectively, were recorded as debt discount and amortized to interest expense over the term of the notes.
[2]	As of December 31, 2014, convertible notes with an aggregate principal balance of $175,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.
[3]	During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to June 10, 2014, the aggregate principal balance of the notes was increased from $90,000 to $105,000. The aggregate $15,000 of principal increases was accreted as interest expense. During the year ended December 31, 2014, $7,500 of the principal increases was settled by the conversion of a convertible note with a maturity date of January 8, 2014 and original principal balance of $30,000 into shares of the Company's common stock.
[4]	As of March 31, 2015, convertible notes with an aggregate principal balance of $155,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.
[5]	During the year ended December 31, 2014, in connection with the extension of certain notes payable with maturity dates ranging from of August 8, 2013 to March 1, 2014, an aggregate $108,059 of accrued interest was added to the aggregate principal balance of the notes, increasing the aggregate principal balance from $742,500 to $850,559.

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Federal and state net operating losses	$12,700,000	$14,000,000
Operating Loss Carry forwards Expiration Period	The net operating loss carry forwards, if not utilized, will expire from 2029 to 2034 for federal purposes.
Percentage of ownership changes	50.00%
Description for Section 382 limitation One	approximately $5,700,000 of federal NOLs not being realizable
Description for Section 382 limitation two	the reversal of approximately $2,200,000 of net operating loss deferred tax assets.

Loss_before_income_taxes_Detai

Loss before income taxes (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Before Income Tax Domestic And Foreign [Line Items]
United States	($5,223,749)	($5,328,958)
Foreign	-363,863	-422,236
Loss before income taxes	($5,587,612)	($5,751,194)

Deferred_Tax_Assets_Detail

Deferred Tax Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets:
Net operating loss carryforward	$4,820,500	$5,327,000
Stock-based compensation	1,272,600	907,100
Accruals	240,700	139,800
Research & development tax credits	95,500	0
Other	2,100	2,700
Gross deferred tax assets	6,431,400	6,376,600
Deferred Tax Liabilities:
Intangible assets	-93,200	0
Fixed assets	-8,100	-3,000
Gross deferred tax liabilities	-101,300	-3,000
Net deferred tax assets	6,330,100	6,373,600
Valuation allowance	-6,330,100	-6,373,600
Deferred tax asset, net of valuation allowance	0	0
Changes in valuation allowance	($43,500)	$1,631,300

Income_Tax_Provision_benefit_D

Income Tax Provision (benefit) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Federal:
Current	$0	$0
Deferred	38,921	-1,459,584
State and local:
Current	0	0
Deferred	4,579	-171,716
Income tax provision (benefit) before change in valuation allowance	43,500	-1,631,300
Change in valuation allowance	-43,500	1,631,300
Income tax provision (benefit)	$0	$0

Statutory_Federal_Income_Tax_R

Statutory Federal Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Tax benefit at federal statutory rate	-34.00%	-34.00%
State income taxes, net of federal benefit	-4.00%	-4.00%
Permanent differences	0.80%	5.80%
Research & development tax credits	-1.80%	0.00%
Impact of Section 382 limit	41.20%	0.00%
True-ups and other	-1.40%	1.60%
Change in valuation allowance	-0.80%	30.60%
Effective income tax rate	0.00%	0.00%

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	0 Months Ended			1 Months Ended				3 Months Ended		12 Months Ended		0 Months Ended				1 Months Ended		0 Months Ended		1 Months Ended					0 Months Ended				1 Months Ended					0 Months Ended	1 Months Ended
	Mar. 09, 2015	Jan. 23, 2015	Oct. 07, 2014	Aug. 13, 2014	Feb. 04, 2014	Jun. 27, 2014	Feb. 20, 2014	Nov. 30, 2013	Jan. 20, 2011	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 12, 2014	Oct. 08, 2014	Feb. 09, 2015	Oct. 04, 2010	Sep. 24, 2014	Jul. 23, 2014	Jun. 16, 2014	Apr. 06, 2015	Oct. 23, 2014	Oct. 31, 2014	Mar. 12, 2014	Aug. 27, 2014	Jun. 15, 2012	9-May-14	Jun. 10, 2013	Mar. 14, 2014	Jul. 02, 2013	Mar. 27, 2013	Jul. 22, 2014	Dec. 23, 2013	Mar. 20, 2013	Mar. 22, 2013	Feb. 11, 2014	Aug. 25, 2014	29-May-15
																																					sqft
Commitments and Contingencies Disclosure [Line Items]
Grant date value			$15,000				$67,830					$124,200
Warrant exercisable term							3 years
Lease Expiration Date									31-Jan-14
Lease Rent Second Year												6,234
Lease Rent Third Year												6,422
Research and Development Expense										406,856	493,741	1,430,614	1,594,054
Accounts Payable and Accrued Liabilities, Total												43,000	353,000
Stock issued during period, value, issued for services			48,388
Stock-based compensation, stock option granted										600,000		10,575,000	1,145,000
Common stock exercise price										$0.46		$0.41	$0.68
Number of shares called by warrants												190,000	402,500
Initial year Salary			25,000
Percentage Of Increase Salary			28.00%
Employee-related Liabilities												574,278	542,535
Severance Costs	125,000
Salaries, Wages and Officers Compensation, Total													565,000
Loss Contingency, Damages Paid, Value								193,000
Loss contingency damages paid value, warrants issued								80,000
Class of Warrant or Right, Exercise Price of Warrants or Rights												$0.75
Monthly Payments for Leasing					962
Stock Issued During Period, Shares, New Issues				550,000
Leasehold Improvements, Gross												103,582	0
Rent Expense										35,000	11,000	20,380	99,175
Professional Fees										365,069	267,198	1,310,121	779,462
Monthly Payments under Consulting Agreements			15,000			10,000
Monthly Escalating Payments under Consulting Agreements			10,000
Warrants Issued During Period, Number of Warrants		100,000
Allocated Share-Based Compensation Expense										76,647	14,071
Share Based Compensation										371,167	373,499	1,360,296	812,647
Security Deposit										45,900		45,900	0
Loss Contingency Damages Paid Value Per Year								52,000
Loss Contingency, Allegations								The action is associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009.
Warrants Issue One [Member]
Commitments and Contingencies Disclosure [Line Items]
Warrants Issued During Period, Number of Warrants														100,000
Warrants Issued During Period, Exercise Price at Issuance Date														$0.53										0.53
Warrants Issue Two [Member]
Commitments and Contingencies Disclosure [Line Items]
Warrants Issued During Period, Number of Warrants														280,000
Warrants Issued During Period, Exercise Price at Issuance Date														$0.53										0.53
Warrants Issue Three [Member]
Commitments and Contingencies Disclosure [Line Items]
Warrants Issued During Period, Number of Warrants														20,000
Warrants Issued During Period, Exercise Price at Issuance Date														$1.50										1.5
Chief Medical Advisor [Member]
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted							300,000
Common stock exercise price							$0.65
Monthly Payments under Consulting Agreements							10,000								15,000
Monthly Escalating Payments under Consulting Agreements							20,000								20,000
Division President
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted																500,000
Common stock exercise price																$0.46
Severance Costs																150,000
Share Based Compensation Arrangement By Share Based Payment Award Options Grant Intrinsic Value																200,400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																3 years
Warrant [Member]
Commitments and Contingencies Disclosure [Line Items]
Grant date value														23,270										23,270
Allocated Share-Based Compensation Expense														30,096
Common Stock [Member]
Commitments and Contingencies Disclosure [Line Items]
Stock Issued During Period, Shares, Other												595,455
Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock												80,000
Number of shares called by warrants																																						100,000
Minimum
Commitments and Contingencies Disclosure [Line Items]
Warrants exercise price												$0.30	$1.50
Class of Warrant or Right, Exercise Price of Warrants or Rights												$0.50	$0.94
Maximum
Commitments and Contingencies Disclosure [Line Items]
Warrants exercise price												$0.75	$4
Class of Warrant or Right, Exercise Price of Warrants or Rights												$0.75	$2.50
Director
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock						600,000
Grant date value						144,000
Stock options granted exercise price per share						$0.28
Number of shares vest on first anniversary of date of grant						200,000
Number of shares vest on second anniversary of date of grant						200,000
Number Of Shares Vest On Third Anniversary Of Date Of Grant						200,000
Chief Executive Officer
Commitments and Contingencies Disclosure [Line Items]
Employee-related Liabilities													25,000
Salaries, Wages and Officers Compensation, Total	400,000											450,000	600,000				600,000
Salary Reduced												450,000	360,000
Salary Bonus													300,000
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	100,000
Deferred Compensation Arrangement with Individual, Description	The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Companys Compensation Committee, are satisfied.
Chief Executive Officer | Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Salaries, Wages and Officers Compensation, Total												450,000
Salary Reduced												400,000
Consultant
Commitments and Contingencies Disclosure [Line Items]
Stock issued during period shares for services										312,795									30,000
Stock issued during period, value, issued for services										85,128		33,000
Stock-based compensation, stock option granted							500,000											75,000		60,000
Common stock exercise price							$0.32											$0.33		$0.39
Number of shares immediately vest on date of grants												150,000
Non Employee Director Awards
Commitments and Contingencies Disclosure [Line Items]
Accounts Payable and Accrued Liabilities, Total												105,000	130,000
Board of Directors
Commitments and Contingencies Disclosure [Line Items]
Salaries, Wages and Officers Compensation, Total						80,000
Compensation Paid To Directors Aggregate Amount						30,000
Compensation Paid To Directors Instalment Amount						50,000
Share Based Compensation						96,250
Board of Directors | Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted																					300,000
Common stock exercise price																					$0.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																					3 years
Employees and Directors
Commitments and Contingencies Disclosure [Line Items]
Grant date value												15,000
Stock issued during period, value, issued for services																							5,000
Stock-based compensation, stock option granted												36,786										5,950,000		2,415,000
Common stock exercise price																						$0.33
Monthly Payments under Consulting Agreements																							10,000
Employees and Directors | Minimum
Commitments and Contingencies Disclosure [Line Items]
Common stock exercise price																								0.53
Employees and Directors | Maximum
Commitments and Contingencies Disclosure [Line Items]
Common stock exercise price																								0.65
Business Advisory Services
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted																									300,000
Business Advisory Services | Extension 1
Commitments and Contingencies Disclosure [Line Items]
Warrant exercisable term						5 years
Marketing Consulting Services
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock						250,000
Exercise price of warrant						$1
Marketing Consulting Services | Consultant
Commitments and Contingencies Disclosure [Line Items]
Contractual Obligation						65,000
Consulting Expense In Shares						500,000
Business Advisory Services Immediately Vesting
Commitments and Contingencies Disclosure [Line Items]
Consulting expense																									75,000
16-Aug-15
Commitments and Contingencies Disclosure [Line Items]
Number of shares vest on first anniversary of date of grant						150,000
16-Aug-16
Commitments and Contingencies Disclosure [Line Items]
Number of shares vest on second anniversary of date of grant						150,000
Assignment Agreement
Commitments and Contingencies Disclosure [Line Items]
Cash payment in exchange for patents																										15,000
Percentage of royalty agreed to be paid																										5.00%
Royalty Period																										20 years
Research and Development Arrangement
Commitments and Contingencies Disclosure [Line Items]
Cash payment in exchange for patents																										500,000
Percentage of royalty agreed to be paid																										5.00%
Royalty Period																										20 years
Research and Development Expense												264,000	500,000
Professional Fees												323,336															208,335
Accrued Professional Fees																											104,168
Gain On Settlement Related To Agreement																											166,668
Agreement Expiration Date																											14-Jun-15
Research and Development Arrangement | Minimum
Commitments and Contingencies Disclosure [Line Items]
Fees payable for services per month																											20,000
Research and Development Arrangement | Maximum
Commitments and Contingencies Disclosure [Line Items]
Fees payable for services per month																											41,667
Marketing Consulting Services Agreement
Commitments and Contingencies Disclosure [Line Items]
Warrant exercisable term						5 years
Consulting expense												82,500	120,000
Marketing Consulting Services Agreement | Warrant [Member]
Commitments and Contingencies Disclosure [Line Items]
Grant date value						37,500
Marketing Consulting Services Agreement | Common Stock [Member]
Commitments and Contingencies Disclosure [Line Items]
Grant date value						110,000
Business Advisory Services | Extension 1
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock						250,000
Exercise price of warrant						$1
Grant date value						37,500
Additional Monthly Fee For Services Rendered						16,667
Business Advisory Services | Extension 2
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock						100,000
Exercise price of warrant						$0.50
Grant date value						17,000
Additional Monthly Fee For Services Rendered						15,000
Consulting expense												150,000	120,000
Chief Executive Officer Employment Agreements
Commitments and Contingencies Disclosure [Line Items]
Restructuring Reserve, Current												175,000
Severance Costs	125,000
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	300,000
Scientific Advisory Services
Commitments and Contingencies Disclosure [Line Items]
Grant date value																													5,860	47,960	45,900
Warrant exercisable term						10 years																						5 years	5 years	10 years	10 years
Recognized granted fair value award																												2,056
Total options granted						300,000																						5,000	25,000	100,000	60,000
Stock options granted exercise price per share						$0.28																						$1	$0.50	$1	$1.50
Number of shares immediately vest on date of grants						81,000																							5,000		30,000
Number of shares vest on first anniversary of date of grant																													12,500	50,000
Number of shares vest on second anniversary of date of grant																													12,500	50,000	30,000
Other
Commitments and Contingencies Disclosure [Line Items]
Warrant issued for the purchase of common stock																																10,000	100,000	10,000	100,000
Grant date value																																1,500	16,770	6,600	59,000
Warrant exercisable term																																5 years	5 years	3 years	5 years
Additional vested common stock shares												474,373	129,537
Additional Vested Common Stock Value												159,837	77,555
Warrants exercise price																																$0.75	$2	$1.50	$4
Stem Cell Treatment Company
Commitments and Contingencies Disclosure [Line Items]
Monthly Payments for Leasing																																				100
Payments for Leasing Per Day																																				3,750
Melville Lease
Commitments and Contingencies Disclosure [Line Items]
Number of shares called by warrants																																					142,100
Class of Warrant or Right, Exercise Price of Warrants or Rights																																					$0.50
Land Subject to Ground Leases																																					6,800
Land Lease Term																																					63 months
Stock Issued During Period, Shares, Other																																					284,200
Description Of Leasing Arrangement Consideration																																					(i) $60,000 towards the leasehold improvements of the leased premises and (ii) $11,050 of prepaid rent for the fifth month of the lease.
Stock Issued During Period, Shares, New Issues												71,050
Leasehold Improvements, Gross												60,000
Prepaid Rent												11,050
Security Deposit												45,900
Melville Lease | Minimum
Commitments and Contingencies Disclosure [Line Items]
Accrued Rent																																					132,600
Melville Lease | Maximum
Commitments and Contingencies Disclosure [Line Items]
Accrued Rent																																					$149,260

Stockholders_Deficiency_Additi

Stockholders' Deficiency - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended		12 Months Ended		0 Months Ended	6 Months Ended	1 Months Ended								0 Months Ended	1 Months Ended
	Oct. 07, 2014	Aug. 13, 2014	Nov. 27, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Oct. 04, 2013	Dec. 30, 2014	Nov. 17, 2014	Oct. 27, 2014	Oct. 23, 2014	Oct. 31, 2014	Mar. 12, 2014	Jan. 23, 2015	Sep. 24, 2014	Jul. 23, 2014	Jun. 16, 2014	Feb. 20, 2014	Jan. 01, 2015	Dec. 19, 2014	Apr. 15, 2013	8-May-14	Feb. 18, 2014
Stockholders Equity Note Disclosure [Line Items]
Stock issued (in shares)		550,000
Sales of common stock and warrants for cash				$801,000	$545,000	$2,605,000	$905,000
Warrants to purchase common stock						2,330,693	403,590
Warrants aggregate grant date fair value						389,608	224,313
Weighted average estimated fair value of stock warrants granted, per share				$0.40	$0.23
Stock-based compensation expense				76,647	14,071
Share granted vested								490,000						831,669
Weighted average estimated fair value of stock options granted						$0.27	$0.26
Stock-based compensation, stock option granted				600,000		10,575,000	1,145,000
Stock-based compensation, stock options granted, exercise price				$0.46		$0.41	$0.68
Common stock, Authorized				200,000,000		200,000,000	200,000,000													200,000,000	20,000,000	100,000,000
Common stock, par value				$0.00		$0.00	$0.00
Preferred stock, Authorized				5,000,000		5,000,000	5,000,000													5,000,000	1,000,000
Preferred stock, par value				$0.01		$0.01	$0.01
Proceeds from Warrant Exercises				0	80,000	113,000	505,809
Warrant modification charge				5,900		50,035	214,912
Warrant redemption terms			The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $1.25 for five consecutive trading days.
Received non-interest bearing advances from officer				84,015		60,055
Repayments Short Term Advances				135,030		60,055
Debt Instrument, Face Amount		4,000,000				7,500
Stock Issued During Period, Value, Issued for Services	48,388
Bermuda Lender | Research and Development Arrangement [Member]
Stockholders Equity Note Disclosure [Line Items]
Debt Instrument Prepayments of Debt						266,297
Debt Instrument, Face Amount																							177,237
Subsequent Event [Member]
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																				200,000,000
Preferred stock, Authorized																				5,000,000
Debt Instrument, Face Amount						50,000
Warrant Exercise And Reload Program [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price			0.3
Exercise price of redeemable warrant to be issued			0.75
Warrants excluded from computation of weighted average price of warrants granted						376,667
Exercise Price Dollor One Point Five Zero
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted				700,000		700,000
Share based compensation shares authorized under stock option plans exercise price				$1.50		$1.50
Exercise Price Dollor One Point Five Zero | Warrant Exercise And Reload Program [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted							1,686,029
Exercise Price Dollor Zero Point Three Zero
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted						376,667	1,686,029
Legal Counsel
Stockholders Equity Note Disclosure [Line Items]
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued								50,000	150,000
Grant date fair value								12,500	33,000
Treasury Stock [Member]
Stockholders Equity Note Disclosure [Line Items]
Proceeds from Warrant Exercises						0	0
Warrant modification charge				0		0	0
First Anniversary Of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested								490,000							75,000
Second Anniversary of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested														1,589,331	12,500
Third Anniversary Of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested															12,500
Employee
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted										100,000
Stock-based compensation, stock options granted, exercise price										$0.33
Stock-based compensation, stock options granted, grant date fair value										31,600
Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted											250,000
Stock-based compensation, stock options granted, exercise price											$0.34
Stock-based compensation, stock options granted, grant date fair value											78,500
Employees and Directors
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted						36,786						5,950,000		2,415,000
Stock-based compensation, stock options granted, exercise price												$0.33
Stock-based compensation, stock options granted, grant date fair value												1,710,400
Stock Issued During Period, Value, Issued for Services													5,000
Employees, Directors and an Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted								980,000							100,000
Stock-based compensation, stock options granted, exercise price								$0.60							$0.47
Consultant
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted																75,000		60,000	500,000
Stock-based compensation, stock options granted, exercise price																$0.33		$0.39	$0.32
Stock-based compensation, stock options granted, grant date fair value																20,100		18,600
Stock Issued During Period, Shares, Issued for Services				312,795													30,000
Stock Issued During Period, Value, Issued for Services				85,128		33,000
Warrants
Stockholders Equity Note Disclosure [Line Items]
Weighted average estimated fair value of stock warrants granted, per share				$0.16	$0.22	$0.17	$0.36
Stock-based compensation expense				0	53,726
Warrants | Warrant Exercise And Reload Program [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price						$0.30	$0.30
Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense				294,520	305,702	874,193	647,815
Unrecognized stock-based compensation expense						2,328,885
Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Period For Recognition				2 years 4 months 24 days		2 years 7 months 6 days
Non Employee Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense				331,341
Consultant Awards | Warrants
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense						185,266	26,777
Consultant Awards | Non Employee Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense						448,189
Employee Awards
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, grant date fair value								199,921						566,483	39,200
Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized												20,000,000									100,000,000
Common Stock
Stockholders Equity Note Disclosure [Line Items]
Stock issued (in shares)				2,703,333		8,671,983	840,589
Sales of common stock and warrants for cash				801,000
Warrants to purchase common stock				850,833
Warrants aggregate grant date fair value				138,383
Minimum
Stockholders Equity Note Disclosure [Line Items]
Shares issued, per share						$0.25	$0.85
Warrants exercise price						$0.30	$1.50
Estimated Forfeitures Related To Option Grants Annual Rate						0.00%	0.00%
Minimum | Employees and Directors
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, exercise price														0.53
Minimum | Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																								6,000,000
Minimum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Shares issued, per share				$0.25
Warrants exercise price				$0.40
Estimated Forfeitures Related To Option Grants Annual Rate				0.00%	0.00%
Maximum
Stockholders Equity Note Disclosure [Line Items]
Shares issued, per share						$0.45	$1.50
Warrants exercise price						$0.75	$4
Estimated Forfeitures Related To Option Grants Annual Rate						5.00%	5.00%
Maximum | Employees and Directors
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, exercise price														0.65
Maximum | Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																								12,000,000
Maximum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Shares issued, per share				$0.30
Warrants exercise price				$0.75
Estimated Forfeitures Related To Option Grants Annual Rate				5.00%	5.00%
Professional Services
Stockholders Equity Note Disclosure [Line Items]
Stock Issued During Period, Shares, Issued for Services				18,847
Stock Issued During Period, Value, Issued for Services				$8,481

BlackScholes_Option_Pricing_Mo

Black-Scholes Option Pricing Model to Warrant Granted, Weighted Average Assumptions (Detail) (Warrants)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years
Expected volatility	122.00%	121.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.22%	0.39%	0.39%	0.34%
Expected term (years)		1 year 11 months 16 days	1 year 11 months 16 days	3 years
Expected volatility			116.00%	132.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.61%	2.20%	2.20%	1.68%
Expected term (years)		5 years	5 years	5 years
Expected volatility			122.00%	135.00%

Summary_of_Warrant_Activity_De

Summary of Warrant Activity (Detail) (Warrants, USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Warrants
Number of Warrants
Beginning Balance	8,248,683	4,795,890		3,334,800
Granted	850,833	3,849,460		3,147,119
Exercised	0	-376,667		-1,686,029
Forfeited	0	-20,000		0
Ending Balance	9,099,516	8,248,683		4,795,890
Exercisable	8,399,516	7,548,683
Weighted Average Exercise Price
Beginning Balance	$0.90	$1.39		$1.69
Granted	$0.68	$0.70		$1.56
Exercised	$0	$0.30	[1]	$0.30	[1]
Forfeited	$0	$0.50		$0
Ending Balance	$0.88	$0.90		$1.39
Exercisable	$0.83	$0.84
Weighted Average Remaining Life In Years
Outstanding	3 years 1 month 6 days	3 years 2 months 12 days
Exercisable	3 years 2 months 12 days	3 years 3 months 18 days
Aggregate Intrinsic Value
Outstanding	$0	$0
Exercisable	$0	$0
[1]	During the year ended December 31, 2013, warrants to purchase an aggregate of 1,686,029 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program. During the year ended December 31, 2014, warrants to purchase an aggregate of 376,667 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program.

Summarized_Information_Related

Summarized Information Related to Stock Warrants (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	9,099,516		8,248,683
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 2 months 12 days		3 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	8,399,516		7,548,683	[1]
Exercise Price 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.3		0.3
Warrants Outstanding, Number of Warrants	650,000		650,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 2 months 12 days		4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	650,000		650,000
Exercise Price 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.4		0.4
Warrants Outstanding, Number of Warrants	250,000		200,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 8 months 12 days		4 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	250,000		200,000
Exercise Price 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.5		0.5
Warrants Outstanding, Number of Warrants	677,100		502,100
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 8 months 12 days		4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	677,100		502,100
Exercise Price 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.53		0.53
Warrants Outstanding, Number of Warrants	380,000		380,000
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 1 month 6 days		3 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	380,000		380,000
Exercise Price 5
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.58		0.58
Warrants Outstanding, Number of Warrants	50,000		50,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 6 months		4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	50,000		50,000
Exercise Price 6
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.75		0.75
Warrants Outstanding, Number of Warrants	4,669,222		4,043,389
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 10 months 24 days		2 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	4,669,222		4,043,389
Exercise Price 7
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.94		0.94
Warrants Outstanding, Number of Warrants	50,000		50,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 6 months		4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	50,000		50,000
Exercise Price 8
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	1		1
Warrants Outstanding, Number of Warrants	550,000		550,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 2 months 12 days		4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	550,000		550,000
Exercise Price 9
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	1.5		1.5
Warrants Outstanding, Number of Warrants	862,800		862,800
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 2 months 12 days		2 years 6 months
Warrants Exercisable, Exercisable Number of Warrants	862,800		862,800
Exercise Price 10
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	1.75		1.75
Warrants Outstanding, Number of Warrants	20,000		20,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years		2 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	20,000		20,000
Exercise Price 11
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	2		2
Warrants Outstanding, Number of Warrants	123,530		123,530
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 7 months 6 days		3 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	123,530		123,530
Exercise Price 12
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	2.5		2.5
Warrants Outstanding, Number of Warrants	20,000		20,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 3 months 18 days		2 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants	20,000		20,000
Exercise Price 13
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	3		3
Warrants Outstanding, Number of Warrants	36,864		36,864
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 1 month 6 days		3 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	36,864		36,864
Exercise Price 14
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	4		4
Warrants Outstanding, Number of Warrants	60,000		60,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 6 months		2 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	60,000		60,000
Exercise Price 15
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, Exercise Price Description	Variable	[2]	Variable
Warrants Outstanding, Number of Warrants	700,000		700,000
Warrants Exercisable, Weighted Average Remaining Life In Years	0 years		0 years	[1]
Warrants Exercisable, Exercisable Number of Warrants	0		0	[1]
[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2014.
[2]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur as of March 31, 2015.

BlackScholes_Option_Pricing_Mo1

Black-Scholes Option Pricing Model to Stock Option Granted, Weighted Average Assumptions (Detail) (Stock Options)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.50%
Expected volatility	122.00%	121.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.33%		1.50%	1.13%
Expected term (years)	5 years	5 years	5 years	5 years
Expected volatility			116.00%	132.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.64%		2.54%	2.66%
Expected term (years)	6 years	5 years 6 months	10 years	10 years
Expected volatility			122.00%	135.00%

Information_Related_to_Stock_O

Information Related to Stock Option Expense (Detail) (USD $)	3 Months Ended			12 Months Ended
	Mar. 31, 2015		Mar. 31, 2014	Dec. 31, 2014		Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$76,647		$14,071
Unrecognized expense	0
Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	294,520		305,702	874,193		647,815
Unrecognized expense	2,203,230			2,328,885
Weighted Average Amortization Period (Years)	2 years 4 months 24 days			2 years 7 months 6 days
Consulting | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	96,803		100,613	365,825		160,894
Unrecognized expense	585,273			654,956
Weighted Average Amortization Period (Years)	2 years 3 months 18 days			2 years 7 months 6 days
Research and development | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	128,432		121,390	328,740		251,758
Unrecognized expense	755,231	[1]		712,551	[2]
Weighted Average Amortization Period (Years)	2 years 4 months 24 days			2 years 6 months
General and administrative | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	69,285		83,699	179,628		235,163
Unrecognized expense	$862,726			$961,378
Weighted Average Amortization Period (Years)	2 years 4 months 24 days			2 years 7 months 6 days
[1]	Includes $331,341 of expense that is subject to non-employee mark-to-market adjustments.
[2]	Includes $448,189 of expense that is subject to non-employee mark-to-market adjustments.

Summary_of_Stock_Option_Activi

Summary of Stock Option Activity (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of Options
Outstanding	15,584,000	5,043,000	4,018,000
Granted	600,000	10,575,000	1,145,000
Exercised	0	0	0
Forfeited	0	-34,000	-120,000
Outstanding	16,184,000	15,584,000	5,043,000
Exercisable	7,196,502	6,371,502
Weighted Average Exercise Price
Outstanding	$0.61	$1.03	$1.12
Granted	$0.46	$0.41	$0.68
Exercised	$0	$0	$0
Forfeited	$0	$1.31	$0.50
Outstanding	$0.60	$0.61	$1.03
Exercisable	$0.88	$0.91
Weighted Average Remaining Life In Years
Outstanding	8 years 3 months 18 days	8 years 6 months
Exercisable	7 years 6 months	7 years 7 months 6 days
Intrinsic Value
Outstanding	$587,850	$979,600
Exercisable	$28,850	$45,600

Information_Related_to_Stock_O1

Information Related to Stock Options (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	16,184,000	15,584,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 6 months	7 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	7,196,502	6,371,502
Exercise Price 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.285	0.285
Options Outstanding, Number of Options	900,000	900,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 2 months 12 days	9 years 6 months
Options Exercisable, Exercisable Number of Options	200,000	200,000
Exercise Price 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.32	0.32
Options Outstanding, Number of Options	500,000	500,000
Options Exercisable, Weighted Average Remaining Life In Years	0 years	0 years
Options Exercisable, Exercisable Number of Options	0	0
Exercise Price 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.33	0.33
Options Outstanding, Number of Options	6,125,000	6,125,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 6 months	4 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	75,000	75,000
Exercise Price 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.34	0.34
Options Outstanding, Number of Options	250,000	250,000
Options Exercisable, Weighted Average Remaining Life In Years	0 years	0 years
Options Exercisable, Exercisable Number of Options	0	0
Exercise Price 5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.39	0.39
Options Outstanding, Number of Options	60,000	60,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 2 months 12 days	4 years 6 months
Options Exercisable, Exercisable Number of Options	60,000	60,000
Exercise Price 6
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.46	0.5
Options Outstanding, Number of Options	500,000	345,000
Options Exercisable, Weighted Average Remaining Life In Years	0 years	4 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	0	332,500
Exercise Price 7
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.47	0.53
Options Outstanding, Number of Options	100,000	40,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 9 months 18 days	9 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	87,500	40,000
Exercise Price 8
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.5	0.6
Options Outstanding, Number of Options	345,000	980,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 7 months 6 days	8 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	345,000	980,000
Exercise Price 9
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.53	0.65
Options Outstanding, Number of Options	40,000	2,675,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 10 months 24 days	9 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	40,000	1,125,002
Exercise price 10
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.6	1
Options Outstanding, Number of Options	980,000	131,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 6 months	8 years
Options Exercisable, Exercisable Number of Options	980,000	131,000
Exercise Price 11
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.65	1.05
Options Outstanding, Number of Options	2,675,000	2,270,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 7 months 6 days	7 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	1,850,002	2,270,000
Exercise Price 12
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1	1.1
Options Outstanding, Number of Options	131,000	5,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 8 months 12 days	2 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	131,000	5,000
Exercise Price 13
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.05	1.2
Options Outstanding, Number of Options	2,270,000	10,000
Options Exercisable, Weighted Average Remaining Life In Years	6 years 10 months 24 days	1 year 4 months 24 days
Options Exercisable, Exercisable Number of Options	2,270,000	10,000
Exercise Price 14
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.1	1.25
Options Outstanding, Number of Options	5,000	43,000
Options Exercisable, Weighted Average Remaining Life In Years	2 years 2 months 12 days	1 year 10 months 24 days
Options Exercisable, Exercisable Number of Options	5,000	43,000
Exercise Price 15
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.2	1.4
Options Outstanding, Number of Options	10,000	350,000
Options Exercisable, Weighted Average Remaining Life In Years	1 year 2 months 12 days	4 years 6 months
Options Exercisable, Exercisable Number of Options	10,000	200,000
Exercise price 16
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.25	1.5
Options Outstanding, Number of Options	43,000	900,000
Options Exercisable, Weighted Average Remaining Life In Years	1 year 7 months 6 days	7 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	43,000	900,000
Exercise Price 17
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.4
Options Outstanding, Number of Options	350,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	200,000
Exercise Price 18
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.5
Options Outstanding, Number of Options	900,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	900,000

Information_Related_to_Common_

Information Related to Common Stock Award Expense (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$76,647	$14,071
Unrecognized expense	0
Common Stock Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense			300,837	138,055
Unrecognized expense			0
Consulting | Common Stock Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	67,800	10,000	276,500	111,351
Unrecognized expense	0		0
Research and development | Common Stock Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	8,847	4,071	24,337	26,704
Unrecognized expense	$0		$0

Summary_of_Common_Stock_Award_

Summary of Common Stock Award Activity (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value, Granted	$0.40	$0.23
Common Stock Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	0	0	0	0
Number of Shares, Granted	312,795		1,943,747	239,537
Number of Shares, Vested	-312,795		-1,943,747	-239,537
Numberof Shares, Forfeited	0		0	0
Number of Shares, Ending Balance	0		0	0
Weighted Average Grant Date Fair Value, Beginning Balance	$0	$0	$0	$0
Weighted Average Grant Date Fair Value, Granted	$0.27		$0.26	$0.58
Weighted Average Grant Date Fair Value, Vested	($0.27)		($0.26)	$0.58
Weighted Average Grant Date Fair Value, Forfeited	$0		$0	$0
Weighted Average Grant Date Fair Value, Ending Balance	$0		$0	$0
Total Grant Date Fair Value, Beginning Balance	$0	$0	$0	$0
Total Grant Date Fair Value, Granted	85,128		511,886	138,055
Total Grant Date Fair Value, Vested	-85,128		-511,886	-138,055
Total Grant Date Fair Value, Forfeited	0		0	0
Total Grant Date Fair Value, Ending Balance	$0		$0	$0

Subsequent_Events_Additional_I

Subsequent Events- Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Mar. 09, 2015

Jan. 23, 2015

Oct. 07, 2014

Aug. 13, 2014

Mar. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Mar. 26, 2013

Feb. 09, 2015

Mar. 12, 2014

Sep. 24, 2014

Jul. 23, 2014

Jun. 16, 2014

Feb. 20, 2014

14-May-15

11-May-15

27-May-15

Apr. 06, 2015

8-May-15

20-May-15

21-May-15

8-May-14

Dec. 02, 2014

2-May-14

Dec. 18, 2013

29-May-15

Subsequent Event [Line Items]

Number of shares called by warrants

190,000

402,500

Warrants Issued During Period, Number of Warrants

100,000

Warrants Issued During Period, Exercise Price

$0.47

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

600,000

10,575,000

1,145,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$0.46

$0.41

$0.68

Stock Issued During Period, Shares, New Issues

550,000

Stock Issued During Period, Value, New Issues

$801,000

Stock Issued During Period, Value, Issued for Services

48,388

Debt Instrument, Face Amount

4,000,000

7,500

Received non-interest bearing advances from officer

84,015

60,055

Repayments Short Term Advances

135,030

60,055

Severance Payment

125,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.75

Long-term Debt, Gross

83,333

Debt Conversion, Original Debt, Amount

30,000

Bermuda Lender [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues

600,000

Stock Issued During Period, Value, New Issues

480,000

Debt Instrument, Interest Rate, Effective Percentage

11.00%

15.00%

Long-term Debt, Gross

83,333

500,000

Debt Instrument, Maturity Date

31-Jul-14

Bermuda Lender [Member] | Research and Development Arrangement [Member]

Subsequent Event [Line Items]

Debt Instrument Prepayments of Debt

266,297

Employee Stock Option [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

500,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$0.46

Warrants Issue One [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Number of Warrants

100,000

Warrants Issue Two [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Number of Warrants

280,000

Warrants Issue Three [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Number of Warrants

20,000

Maximum [Member]

Subsequent Event [Line Items]

Debt Instrument, Increase, Accrued Interest

105,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.75

$2.50

Minimum [Member]

Subsequent Event [Line Items]

Debt Instrument, Increase, Accrued Interest

90,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.50

$0.94

Consultant

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

75,000

60,000

500,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$0.33

$0.39

$0.32

Stock Issued During Period, Shares, Issued for Services

312,795

30,000

Stock Issued During Period, Value, Issued for Services

85,128

33,000

Convertible Notes Payable [Member]

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

12.00%

10.00%

12.00%

12.00%

Sale of Stock, Price Per Share

$0.25

Debt Instrument, Face Amount

50,000

Proceeds from Convertible Debt

30,000

Debt Instrument, Interest Rate, Effective Percentage

100.00%

Debt Instrument, Convertible, Conversion Price

$0.10

Debt Instrument Percentage For Fair Value

55.00%

Debt Instrument, Increase, Accrued Interest

5,984

3,646

Sale of Stock, Number of Shares Issued in Transaction

222,245

Long-term Debt, Gross

155,000

175,000

281,000

Convertible Notes Payable [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt Instrument, Convertible, Conversion Price

$0.22

Convertible Notes Payable [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt Instrument, Convertible, Conversion Price

$0.19

Notes Payable, Other Payables [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues

5,000

Notes Payable

Subsequent Event [Line Items]

Debt Instrument, Increase, Accrued Interest

13,565

Notes Payable | Maximum [Member]

Subsequent Event [Line Items]

Debt Instrument, Convertible, Conversion Price

$0.28

Notes Payable | Minimum [Member]

Subsequent Event [Line Items]

Debt Instrument, Convertible, Conversion Price

$0.14

Chief Medical Advisor [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

300,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$0.65

Subsequent Event

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

12.00%

Number of shares called by warrants

100,000

Sale of Stock, Price Per Share

$0.25

Debt Instrument, Face Amount

50,000

Proceeds from Convertible Debt

30,000

Debt Instrument, Convertible, Conversion Price

$0.10

Debt Instrument Percentage For Fair Value

55.00%

Debt Instrument, Increase, Accrued Interest

5,984

Sale of Stock, Number of Shares Issued in Transaction

222,245

Warrant Issued To Purchase Common Stock

80,000

Investment Warrants, Exercise Price

$0.75

Subsequent Event | Lenders [Member]

Subsequent Event [Line Items]

Number of shares called by warrants

140,000

Class of Warrant or Right, Outstanding

256,808

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.75

Warrants Exercisable Term

5 years

Long-term Debt, Gross

282,873

Debt Conversion Original Debt Accrued Interest Amount

25,296

Debt Conversion, Converted Instrument, Shares Issued

1,027,231

Subsequent Event | Cayman and the Bermuda Lender [Member]

Subsequent Event [Line Items]

Long-term Debt, Gross

410,938

Debt Instrument Unpaid Principle Balances Amount

316,297

Debt Instrument, Maturity Date

30-Jun-15

Subsequent Event | Bermuda Lender [Member]

Subsequent Event [Line Items]

Number of shares called by warrants

800,000

Class of Warrant or Right, Outstanding

3,733,645

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.75

Warrants Exercisable Term

5 years

Long-term Debt, Gross

4,410,938

Debt Conversion Original Debt Accrued Interest Amount

69,436

Debt Conversion, Converted Instrument, Shares Issued

14,934,578

Subsequent Event | In Process Research and Development [Member]

Subsequent Event [Line Items]

Payments for (Proceeds from) Other Investing Activities

177,234

Subsequent Event | Japanese Pharmaceutical Company [Member]

Subsequent Event [Line Items]

Payments for (Proceeds from) Other Investing Activities

50,000

Subsequent Event | Maximum [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Exercise Price

$0.75

Subsequent Event | Minimum [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Exercise Price

$0.40

Subsequent Event | Chief Executive Officer [Member]

Subsequent Event [Line Items]

Annual Salary

400,000

Description for annual bonus of each year

The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary

Description for Chief Executive Officer receive severance amount one

the CEO would be entitled to receive severance in an amount equal to one time his then annual base salary and certain benefits, plus $100,000 (in lieu of bonus).

Description for Chief Executive Officer receive severance amount two

the CEO would be entitled to receive severance in an amount equal to one and one-half times his then annual base salary and certain benefits, plus $300,000 (in lieu of bonus).

Subsequent Event | Board of Directors Chairman [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

300,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$0.40

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

10 years

Subsequent Event | Convertible Notes Payable [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

100,000

Debt Instrument, Interest Rate, Effective Percentage

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

The convertible note is payable as follows: (i) $25,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the “First Maturity Date”), (ii) $25,000 of principal and the respective accrued interest on such principal is payable two weeks following the First Maturity Date (the “Second Maturity Date”), (iii) $25,000 of principal and the respective accrued interest on such principal is payable four weeks following the First Maturity Date (the “Third Maturity Date”) and (iv) $25,000 of principal and the respective accrued interest on such principal is payable six weeks following the First Maturity Date (the “Fourth Maturity Date”). Each $25,000 of principal and the respective accrued interest on such principal is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at a conversion price equal to the greater of (a) 62% of the fair value of the Company’s stock or (b) $0.15 per share.

Subsequent Event | Convertible Notes Payable One [Member] | Lenders [Member]

Subsequent Event [Line Items]

Number of shares called by warrants

35,000

Class of Warrant or Right, Outstanding

41,667

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.75

Warrants Exercisable Term

5 years

Long-term Debt, Gross

50,000

Debt Conversion, Converted Instrument, Shares Issued

166,667

Subsequent Event | Convertible Notes Payable Two [Member] | Lenders [Member]

Subsequent Event [Line Items]

Number of shares called by warrants

130,000

Class of Warrant or Right, Outstanding

216,667

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.75

Warrants Exercisable Term

5 years

Long-term Debt, Gross

260,000

Debt Conversion, Converted Instrument, Shares Issued

866,667

Subsequent Event | Six-Month Convertible Note [Member]

Subsequent Event [Line Items]

Debt Instrument, Interest Rate, Effective Percentage

10.00%

10.00%

Debt Instrument, Convertible, Conversion Price

$0.22

$0.26

Class of Warrant or Right, Outstanding

126,923

58,929

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.50

$0.50

Warrants Exercisable Term

5 years

5 years

Long-term Debt, Gross

75,000

100,000

50,000

Debt Instrument, Convertible, Terms of Conversion Feature

The convertible note is convertible into shares of the Companys common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to at the greater of (a) 65% of the fair value of the Companys stock or (b) $0.15 per share.

The convertible note is convertible into shares of the Companys common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) 65% of the fair value of the Companys stock; or (b) $0.15 per share.

Debt Conversion Original Debt Accrued Interest Amount

1,205

1,301

Debt Conversion, Original Debt, Amount

25,000

25,000

Debt Conversion, Converted Instrument, Shares Issued

118,043

101,943

Subsequent Event | Investor

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues

700,000

Stock Issued During Period, Value, New Issues

200,000

Class of Warrant or Right, Outstanding

175,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.75

Subsequent Event | Investor | Maximum [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share

$0.30

Subsequent Event | Investor | Minimum [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share

$0.25

Subsequent Event | Investors [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Number of Warrants

850,833

Stock Issued During Period, Shares, New Issues

2,703,333

Stock Issued During Period, Value, New Issues

801,000

Subsequent Event | Investors [Member] | Maximum [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share

$0.30

Subsequent Event | Investors [Member] | Minimum [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share

$0.25

Subsequent Event | Consultants [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Issued for Services

270,295

Stock Issued During Period, Value, Issued for Services

$73,528

Subsequent Event | Consultants [Member] | Immediately Vesting [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

12,500

Subsequent Event | Consultants [Member] | Vesting Over One Year [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

12,500

Subsequent Event | Consultants [Member] | Vesting Over Three Months [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

75,000

Subsequent Event | Consultants and Others [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Issued for Services

144,616

Class of Warrant or Right, Outstanding

600,000

Warrants Exercisable Term

5 years

Subsequent Event | Consultants and Others [Member] | Maximum [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.60

Subsequent Event | Consultants and Others [Member] | Minimum [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.38